Issuu

Annual Report 2025

Acknowledgement of Country

We acknowledge the Gadigal, Bidjigal, Gundungurra and Dharawal people, the traditional custodians of the lands on which the Garvan Institute and Australian BioResources (ABR) are located. We pay respects to Elders, past and present, and recognise their continuing connection and contribution to this land.

Welcome from Garvan's Chairs and Directors

Message from the Chair and Executive Director and CEO of the Garvan Institute.

Scott Perkins Chair

Professor Benjamin Kile Executive Director and CEO

Medical research is at an inflection point. The ﬁelds we pursue at Garvan –cancer, genomics and immunology – are converging in ways that are opening new possibilities for clinical impact.

Our focus on these fields reflects where Garvan has the greatest strength and where we can have the greatest impact. This year we added to that capability with the promotion of Dr Seyhan Yazar and Dr Etienne Masle-Farquhar and the recruitment of Associate Professor Maté Biro to Garvan’s Faculty, with Dr Clare Puttick, Dr Carlson Tsui and Dr Philipp Rommel due to join in 2026.

For the first time, clinical translation, something that has driven us since the Institute was founded, now has a structured, multi-disciplinary central capability. Led by Dr Rachel Galimidi, the growing Biologics Platform completed its first full antibody discovery campaign, which marks a genuine step toward a future where we celebrate the launch of new medicines that have their origins in Garvan science.

In 2025, we started to see how generative AI is going to transform medical research.

It will not just impact on individual lab processes or types of analysis; it will change the way Garvan operates. This may sound a daunting prospect, but with our deep expertise in computational biology, data science and machine learning, we are well placed to capitalise on the possibilities. Our researchers are already working directly with companies like Google and Anthropic – and our intention is to build on those partnerships, to not just be consumers of AI tools, but be active contributors to how those technologies develop.

We also welcomed new Board members Ilana Atlas AO, Sue Horlin, Dr Kate Jeffrey, Dr Andrew Nash and Dr Neil Söderlund. We thank retiring members The Hon Dr Annabelle Bennett AC SC and Professor Ronald Trent for their dedicated service to Garvan.

Garvan is a community of researchers, clinicians, partners and supporters, and it is that collective effort that makes our work possible. What we discover here is for the benefit of patients. That is what drives us.

Garvan pursues the toughest challenges across cancer, immunology and genomic diseases to improve health for all.

Message from the Chair and Director of the Garvan Research Foundation.

Dr

The Garvan Research Foundation is the fundraising, marketing, communications and public engagement arm of the Institute with every dollar raised directed to advancing Garvan’s research and mission.

Looking back on 2025, we are deeply humbled by the extraordinary generosity of our Garvan family – those who give a regular donation, a major philanthropic or corporate gift, engage in community fundraising or are our Partners for the Future, who leave a lasting legacy in their Will. Their incredible support contributed $49.4 million this year, providing critical funding for Garvan’s brightest minds, new Faculty recruits and strategic platforms, accelerating discovery and ensuring that bold ideas have the backing to achieve the greatest clinical impact.

We were delighted to welcome Lauren Sutton to the Garvan Research Foundation Board. Lauren’s professional expertise and multi-generational philanthropic relationship with Garvan and St Vincent’s arrives at a pivotal moment in the scale of Garvan’s aspirations and the history of our remarkable precinct.

A key part of that vision involves the expansion of our Biologics and

Development Platforms under Dr Rachel Galimidi. Thanks to the dedication of our community, Garvan has become the first medical research institute in Australia capable of taking a biologic right through to early-stage clinical trials. This infrastructure will deliver the next generation of innovative treatments, and it would not exist without the confidence our generous donors have in our science.

Through our public engagement program, Garvan endeavours to make medical research accessible to the community it ultimately exists for. In 2025, we celebrated National Science Week by launching our Art of Discovery exhibition, transforming research imagery into large-scale artworks and inviting the public to explore the tension between the beauty of biology and the devastating reality of the diseases we study.

We are funded by the community that we serve – taxpayers and donors alike – and that responsibility and trust drives everything we do. To every member of our Garvan family, we extend our most heartfelt thanks for your continued belief in our work and for standing beside us as we shape the future of medicine.

We are deeply grateful to our Garvan family whose ongoing support catalyses and accelerates our mission.

Mara-Jean Tilley Director

Russell Scrimshaw AM Chair

About Garvan

For over 60 years Garvan has been at the forefront of medical research. Today, we are continuing this legacy, bringing together world-class scientists to solve the most pressing medical challenges.

We see a future where all diseases can be prevented, treated or cured.

A future where every patient receives a timely diagnosis, every cancer has an effective therapy, and every immune disease can be cured.

To make discoveries that improve health for all.

Garvan works at the intersection of cancer, genomics and immunology – fields of enormous unmet clinical need, and fields that are converging in ways that amplify each other’s discoveries and accelerate the development of new therapies. We back our researchers over the long term to pursue the most important scientific questions with rigour, creativity, and technological sophistication. Garvan is building the infrastructure that will ensure our discoveries become medicine.

Where discoveries become cures

For more than 60 years, Garvan has done the hard, fundamental science needed to understand disease – and driven those discoveries towards treatments that have reached patients. Still, too many people facing a diagnosis today are counting on discoveries that haven't been made yet. Garvan is here to make them.

Diseases are linked to our genes, our immune system and the way they interact with environmental factors. Garvan's research focuses on three fields that inform and accelerate each other: genomics, cancer and immunology.

Genomics reveals the molecular basis of disease. Cancer will touch all of us, and the technology and relentless momentum of cancer research is pushing all of medicine forward. Immunology is the connector; almost every human disease interacts with, is shaped by, or can be treated through the immune system. Together, these three fields and their intersections are where the greatest breakthroughs now happen – and where Garvan has built one of the strongest research programs in Australia.

Garvan has always pushed technology further than anyone thought possible – and when the tools to answer a question don't exist, we build them. We have been a leader in machine learning and data science and are developing strategies to ensure Garvan is leveraging AI across all areas of our work. We have become the first medical research institute in Australia capable of advancing biologic medicines from concept to first-in-human studies. It is a global asset that connects Australian discoveries to the world, and the world's advances to Australian patients.

Within the next decade, we will see Garvan research translated into new medicines that treat and cure diseases that have defeated science for generations.

The foundations are in place. The direction is clear. What comes next will change medicine.

Garvan doesn’t wait for technology to catch up. We adapt it, push it further, and when the right tool doesn’t exist, we build it. Because the questions we’re asking are too important to be held back by technical limits.

Research at Garvan

Garvan’s research is focused on cancer, genomics and immunology – three fields where Garvan can have the greatest impact for human health.

At the same time, we have built world-leading infrastructure, technology and capability to accelerate our discoveries toward clinical impact.

Professor Sarah Kummerfeld Chief Scientific Oﬃcer

Three fields, one mission – underpinned by the latest infrastructure and technology to make the biggest impact for our community.

Our Research Programs Our Scientific Platforms

Research Programs Scientific Platforms

Garvan’s more than 300 world-leading scientists work within dedicated Research Programs across our three focus areas. Guided by the understanding that the body’s systems are deeply interconnected, our researchers increasingly work at the intersections of these fields, bringing together diverse expertise to accelerate discovery and transform how we understand and treat disease.

Our researchers' breakthroughs are made possible by their access to the best technology, infrastructure and systems. Garvan has six Scientific Platforms that together underpin and enable all our discoveries. Notably, through our Data Science Platform, we leverage AI throughout our research pipeline. Our Biologics and Development platforms allow us to test and develop novel therapies, ready for early-stage clinical trials – an unrivalled asset that accelerates our discoveries towards patients.

2025 at a glance

Our achievements in numbers.

In 2025, Garvan delivered an exceptional year of impact in medical research, marked by major breakthroughs and clinical translation. We advanced world-leading science in cancer, genomics and immunology, reflected in our strong publication record and engaged with cutting-edge clinical trials and studies. Our talented researchers, staff and students drove international collaborations and deepened our engagement with the community.

Our people

United by our mission to make discoveries that improve health for all

Publications

Delivering world-leading discoveries in cancer, genomics and immunology

721

total staff

247 professional and scientific support staff

410 scientific papers published

388 scientists

86 Honours, Masters and PhD students

3rd in Australia for Nature Index

Clinical trials

Accelerating the translation of research breakthroughs to clinical impact

Public engagement

Disseminating our breakthroughs to the community while educating the public about our vital work

Funding by source

Garvan’s research is supported by a combination of peer-reviewed government grants and generous philanthropic investment from the community we serve.

20 clinical trials and studies launched or progressed

4,100+ media mentions across print, radio, TV and online

2,100+ individuals enrolled as at 2025

3,200+ participated in our public seminars, events and tours

Funding by source

Our precinct

Garvan is a partner of the St Vincent’s Sydney Health Innovation Precinct, Australia’s oldest and most established health partnerships, and is proudly affiliated with UNSW Sydney.

This unique partnership and our co-location enable close and meaningful collaboration with the precinct's other partners, speeding up translation of our discoveries from the lab to the bedside and back again.

Collaboration is key to achieving groundbreaking discoveries. At Garvan, we have extensive, collaborative networks both globally and nationally, which strengthen our research and increase the impact of our work. Here we highlight the number of joint publications with national and international institutions in 2025.

St Vincent’s Clinic

St Vincent’s Private Hospital Sydney

The Kinghorn Cancer Centre

Victor Chang Cardiac Research Institute

St Vincent’s Hospital Sydney Garvan Institute of Medical Research

Research highlights

A year of transformative medical research discoveries and clinical advancement.

How a viral infection can trigger a severe autoimmune disease

We discovered that chronic hepatitis C infection stimulates B cells to continuously mutate. This creates a ‘perfect storm’ of genetic variants, producing rogue clones that drive a debilitating autoimmune disease called cryoglobulinemic vasculitis. This finding opens avenues for new, targeted treatments against this disease.

Refining the genetic test for an inherited heart condition

An international team led by Garvan systematically reviewed and refined the list of genes used to diagnose hypertrophic cardiomyopathy, which can cause sudden cardiac death. The updated gene panel enables a more precise diagnosis and is already being adopted by laboratories worldwide.

A call for greater diversity in genomics research

We found a gene variant once considered rare and diseasecausing is actually common in healthy Oceanian individuals. This reflects the limited diversity in current genomic datasets and highlights the need for broader ethnic representation in genetics research.

Left

right arm?

Why vaccination site matters for immune response

We uncovered that receiving a booster vaccine in the same arm as your first dose can generate a stronger and quicker immune response. This fundamental discovery offers insights to improve future vaccination strategies.

A new AI tool uncovers how cancer cells diﬀer from their neighbours

Together with international researchers, we developed AAnet, a powerful AI tool which detects biological patterns in individual cancer cells in a tumour. By identifying unique cell behaviour, this technology paves the way for more personalised cancer therapies.

In 2025, Garvan researchers achieved remarkable breakthroughs across cancer, genomics and immunology. By combining cuttingedge technology with world-class expertise, we are driving discoveries from the lab to clinical impact.

A

new drug combination to overcome neuroblastoma treatment resistance

Researchers discovered that romidepsin bypasses blocked cellular pathways in relapsed high-risk neuroblastoma. Combined with standard chemotherapy, it reduces tumour growth, offering a promising new treatment strategy for this aggressive childhood cancer.

Strategic highlights

Garvan’s Strategic Plan is designed to empower world-class research and foster a culture of ambition, rigour and excellence.

Bold science requires investing in the systems, people and structures that allow great research to happen. Our 2025-2028 Strategic Plan Accelerating Discovery, Empowering Translation charts a path to achieve this.

Centered around our research strengths of cancer, genomics and immunology and underpinned by five key institutional priorities, it ensures we enable our discoveries, accelerate their translation to the clinic, develop our exceptional talent and build institutional sustainability.

2025 was a year of transforming foundations and creating momentum across the organisation. Here we outline the key strategic developments we achieved against our Strategic Plan.

Discovery

Translation

Development

Engagement

Institutional sustainability

Discovery

We conduct medical research that turns public support into public knowledge.

Major breast cancer grant awarded

Secured a generous $25M grant from the National Breast Cancer Foundation for an ambitious research program called AllClear, which will fund research over the next five years to address the clinical challenge posed by breast cancer relapse.

Expanded

our scientific leadership

Building on our ambitious research strategy, we appointed Associate Professor Maté Biro, Dr Seyhan Yazar and Dr Etienne Masle-Farquhar to Garvan's Faculty, with Dr Clare Puttick, Dr Carlson Tsui and Dr Philipp Rommel due to join in 2026.

New centre to advance cancer research

We announced the establishment of the ACRF MATRIX Centre at Garvan, Australia's first centre dedicated to ultra-high resolution spatial proteomics in cancer.

National genomics infrastructure supported

Established and recruited a lead for the National Scale Genomics Infrastructure initiative, laying the foundation for critical new research capabilities within our Scientific Platforms.

Translation

We translate knowledge into improved prevention, diagnosis and treatment of disease.

First Biologics Platform campaign complete

We delivered the first antibody discovery campaign for the Biologics Platform, demonstrating its readiness for accelerating the discovery and development of nextgeneration protein-based therapies, such as monoclonal antibodies.

Accelerator Fund launched

Launched the Garvan Accelerator Fund, a mechanism to fast-track promising Garvan discoveries through the commercialisation pipeline, from early-stage research findings towards translational and commercial outcomes.

Development

We educate, train and develop world-class researchers and professionals who will become the leaders of the future.

Faculty pathway enhanced

Launched a revised Faculty career pathway to simplify the processes for promoting our most promising early-mid career researchers, ensuring we focus on attracting, recruiting and promoting the best research talent.

Engagement

We engage, inspire and educate the community to deepen the understanding and impact of Garvan’s work and medical research more broadly.

Advocated for the advancement of the medical research sector

Professor Benjamin Kile was appointed as AAMRI NSW Co-Chair, and Professor Sarah Kummerfeld was appointed Chair of the AAMRI NSW AI Working Group, enhancing our external influence and visibility within the medical research sector.

Successfully engaged the community and general public

Expanded our public engagement program, including the successful launch of Garvan's Art of Discovery public exhibition. This exhibition featured Garvan's science images during National Science Week.

Institutional sustainability

We strengthen and enhance the systems that support our mission and enable a high-performing, ever-evolving research culture that drives extraordinary science.

Garvan’s AI strategy launched

Acknowledging the transformative potential of AI, we launched our AI strategy and guidance for use, embedding this technology across all aspects of our work.

IT transformation and Cybersecurity enhancement progressed

Completed Phase 1 of the IT Transformation program of works, revitalising our core systems and structures. We developed and endorsed a new Cyber Resilience Plan, significantly strengthening our defences against evolving digital threats.

Our research focus

Three fields, one mission. We pursue the toughest problems in medicine.

At Garvan, our research centres on three fields: cancer, immunology and genomics. Our focus areas are composed of ambitious Research Programs, each headed by world-leading scientists. Together, these programs tackle the biggest medical research challenges that exist today.

Research Programs Directors

Cancer Ecosystems

Targeting the tumour microenvironment to develop new cancer drugs and diagnostic tests.

Cancer Plasticity and Dormancy

Developing new treatment paradigms to overcome treatment resistance in cancer.

Translational Oncology

Integrating Garvan’s breakthrough research with St Vincent’s Hospital’s world-class cancer care to transform therapies and improve patient outcomes.

Precision Immunology

Transforming the diagnosis and treatment of diseases affecting the immune system.

Immune Biotherapies

Harnessing the power of the immune system to develop new biotherapies and improved vaccines. Professor Robert Brink

Genomics and Inherited Disease

Harnessing genomics to accelerate the diagnosis and treatment of inherited disease.

Translational Genomics

Unpacking disease through the cell and the genome. Professor

Centre for Population Genomics

Building Australia's largest and most inclusive genomic databases to ensure equitable access to genomic health advances. The Centre is a collaboration with the Murdoch Children's Research Institute.

Cancer

Cancer touches almost everyone. Despite advances in early detection, surgery and treatment, cancer remains a major cause of illness in Australia and around the world. That’s why Garvan is dedicated to undertaking fundamental and clinical research which improves the diagnosis and treatment of this disease.

Cancer in context

Almost 1 in 2

Australians will be diagnosed with cancer by age 85

1 million

Australians were diagnosed with cancer in the last 10 years

3 in 10

deaths in Australia are caused by cancer

30-40 yr olds are experiencing increased rates of cancer

Our researchers are studying cancer from every angle; from uncovering how it begins, to how it progresses and how it can come back. Our ultimate goal is to translate these discoveries into better ways to diagnose and treat a broad range of cancers, bringing hope for the millions aﬀected by this disease.

Garvan’s cancer research

At Garvan, our research programs work together to tackle cancer from all angles; from fundamental drivers of disease to translational research, ready to reach patients. Our researchers focus on answering the biggest cancer questions that remain such as:

• What drives treatment resistance and how can we prevent it?

• How can we harness the immune system to combat cancer?

• How can we prevent relapse so that cancer doesn’t come back?

• How can the environment around tumours protect the cancer from destruction?

• How can we improve the diagnosis of cancer?

• Can we better match a patient’s cancer to the right treatment to improve outcomes?

At the same time, our state-of-the-art platforms and deep collaborations across the St Vincent’s Sydney Health Innovation Precinct and beyond allow our researchers to accelerate the path from new cancer discoveries to the development and testing of new treatments.

224 staff and students

18 labs and groups

164 research papers published

$34.2M+ secured in new peer-reviewed grants

36 clinical trials and registries with Garvan involvement

The Kinghorn Cancer Centre

The Kinghorn Cancer Centre (TKCC) represents the cornerstone partnership between Garvan and St Vincent’s Hospital Sydney. It unites Garvan's cutting-edge scientific discoveries with world-class clinical care, creating a powerful model for personalised cancer treatment. This collaboration means laboratory breakthroughs can be rapidly translated into improved diagnosis and prevention for people with cancer. Over the past decade, TKCC has supported more than 25,000 patients and enabled the publication of over 770 research discoveries, demonstrating the profound impact of integrating multidisciplinary research with compassionate patient care. Garvan acknowledges the unparalleled support of The Kinghorn Foundation in the establishment of TKCC and its continued investment in breakthrough medical research.

Cancer clinical trials through collaboration

Clinical trials are an essential conduit through which laboratory breakthroughs reach cancer patients. They allow potential new treatments to be tested and ensure that they are safe and effective for preventing and treating cancer.

Through Garvan’s extensive collaboration with other researchers, clinicians and hospitals – including our unique relationship with St Vincent’s Hospital Sydney – our researchers have contributed to 36 clinical trials and studies that were active in 2025. These spanned a variety of cancers, with the majority being prostate and breast cancer trials.

Research highlights

AI tool set to transform characterisation and treatment of cancer

New AI tool uncovers how individual cancer cells behave, which could be integrated into cancer diagnostics to better inform treatment

A multinational research team, co-led by Garvan, developed a new AI tool called AAnet that can help researchers better understand how individual cells behave inside tumours. The findings, co-led by Garvan’s Associate Professor Christine Chaffer and Professor Sarah Kummerfeld, address a newly appreciated characteristic of cancer tumours: that not all cells behave the same. This diversity, or heterogeneity, means each cell in a tumour responds differently to therapies, often leading to treatment resistance.

AAnet was developed to analyse variations in gene expression across individual cancer cells to uncover patterns in how they behave and respond to treatment. Using breast cancer samples and lab models, the tool identified five distinct groups of breast cancer cells, each with unique behaviours.

The development of AAnet opens doors for a paradigm shift in how cancer is treated. Instead of treating tumours as a collection of cells behaving identically, researchers could now target the complex mix of cells within that tumour. Our researchers foresee that these findings will lead to more personalised treatments that result in better outcomes for those with cancer.

We envision a future where doctors combine this AI analysis with traditional cancer diagnoses to develop more personalised treatments that target all cell types within a person’s unique tumour. These results represent a true melding of cutting-edge technology and biology that can improve patient care.

Associate Professor Christine Chaﬀer Co-lead of the study

Associate Professor Christine Chaffer and Professor Sarah Kummerfeld

A metabolism switch that could stop pancreatic cancer spreading

Garvan scientists identiﬁed a molecule that fuels pancreatic cancer spread, opening new avenues for targeted treatment

Our researchers uncovered how pancreatic cancer hijacks a crucial metabolism ‘switch’ to help it spread, revealing a potential new treatment strategy for this aggressive disease. The study identified Neuropeptide Y (NPY) as a key driver of pancreatic cancer metastasis. NPY was found to be significantly higher in pancreatic cancer cells compared to normal tissue. By blocking NPY’s function in laboratory models, the team substantially reduced the spread of cancer to the liver. Surprisingly, blocking NPY also helped reduce the severe loss of muscle and fat tissue mass that often accompanies cancer progression.

The team developed an antibody designed to neutralise NPY’s effect, which is currently being tested. This approach could provide a highly personalised therapy for patients with aggressive, metastatic pancreatic cancer.

By blocking this molecule, we could slow down pancreatic cancer cell movement and metastatic outgrowth in the liver, thereby limiting the spread of the cancer.

Dr Cecilia Chambers First author of the study

Fluorescence imaging of pancreatic cancer tumour

Uncovering a mechanism driving treatment resistance in breast cancer

Inactivation of a stress pathway allows estrogen receptor-positive breast cancer cells to resist new combination therapies

A Garvan study, led by Associate Professor Liz Caldon, uncovered why some breast cancers become resistant to treatment, opening the door to more effective therapies. CDK4/6 inhibitors, combined with endocrine therapy, are now first-line therapy for high-risk estrogen receptor-positive (ER+) breast cancer patients. While this combination has significantly improved survival rates, some patients still experience resistance to this treatment, but we don’t know why.

To address this, Associate Professor Caldon’s team revealed how disruption to a cellular stress response system involving the JNK pathway allows ER+ breast cancer cells to evade this treatment.

The JNK pathway acts like a cellular alarm system; when cells experience stress from cancer treatments, it triggers processes that kill damaged cells or stop them from dividing. The team found that when key genes in this pathway are not functioning properly, cancer cells ignore the message to stop growing. Tumour samples from breast cancer patients showed that those with low JNK pathway activity were less likely to respond well. The team is now investigating what alternative treatments might work for patients with low JNK pathway activity, hoping to develop therapeutic approaches tailored to this group.

Bypassing treatment resistance in deadly childhood cancer

Drug combination found to overcome treatment resistance in relapsed neuroblastoma

A discovery by the David Croucher Lab could lead to better treatment for children with neuroblastoma, an aggressive cancer that claims nine out of 10 young patients who experience relapse. The team found that many standard chemotherapy drugs rely on a cellular ‘switch’ called the JNK pathway to trigger cancer cell death. In relapsed tumours, this switch often stops working, rendering treatments ineffective.

Behind every statistic is someone’s loved one. Understanding these molecular mechanisms gives us hope we can develop more eﬀective treatments for patients and their families.

Associate Professor David Croucher Lead of the study

Looking for alternatives, the researchers identified romidepsin, a drug used for certain lymphomas, as highly potent against neuroblastoma cells even when the JNK pathway is blocked. In laboratory models, combining romidepsin with standard chemotherapy reduced tumour growth and extended survival time. Furthermore, lower doses of standard chemotherapy achieved the same cancer-killing effect when combined with romidepsin, raising the possibility of reduced side effects for young children. The team’s next step is optimising the combination treatment for future clinical trials.

Associate Professor Liz Caldon and Dr Sarah Alexandrou

Neuroblastoma cancer cells

Solving

one of the most urgent challenges: the return of

breast cancer

Ambitious new research project launched to tackle breast cancer relapse

Each year, more than 21,000 Australians are diagnosed with breast cancer. For some, breast cancer cells disseminate from the primary tumour and hide dormant in the body, reawakening years or even decades later to cause therapy-resistant metastases and relapse. In 2025, an ambitious research program called AllClear launched, with the generous support of the National Breast Cancer Foundation. Led by Garvan’s Associate Professor Christine Chaffer, the program focuses on disseminated breast cancer cells – ‘seeds’ of relapse –with the long-term goal of halving breast cancer deaths.

This is a really exciting time in breast cancer research. We have the skills, we have the technology, and we have experts coming together, all centered around this one question: finding these seeds of relapse and eliminating them.

Associate Professor Christine Chaﬀer Lead of the AllClear program

AllClear is using cutting-edge tools to isolate and study these ‘seeds’, refine tools to predict who is most at risk of relapse, and develop targeted therapies to eliminate these cells. Understanding and tackling cancer cell dormancy has the potential to transform how breast cancer is treated, significantly reducing deaths.

Hope for liver cancer patients

New trial targets the unique environment around tumours

Liver cancer is an aggressive disease with poor outcomes – only one in four people survive five years after diagnosis. A clinical trial launched in 2025 hopes to change this dire statistic.

Co-led by Garvan’s Dr Ankur Sharma, the DEFINERx050 trial is testing a combination therapy in early-stage liver cancer to prevent recurrence. The trial is based on a concept underpinning many of Garvan’s research programs: that cancers need both ‘seed’ and ‘soil’ to grow. The cancer cell – seed – needs the right microenvironment – soil – around it to both provide nutrients and suppress the immune system from attacking the cancer cells. In a significant breakthrough, Dr Sharma uncovered that certain reprogramming ‘signatures’ in the microenvironment make liver cancers more aggressive and resistant to treatment.

The trial is testing a combination of approved drugs, given before surgery, to liver cancer patients with these molecular signatures, to see if targeting the tumour microenvironment can stop liver cancer from returning.

If successful, the trial could lead to more precise liver cancer treatments, matching people likely to have aggressive cancer with the right therapy.

How a family’s support of medical research is honouring their cancer story

Michael was just 48 when he received a cancer diagnosis. After his passing, his family chose to support Garvan’s bowel cancer research

When Michael was diagnosed with aggressive metastatic colorectal cancer, his family faced an unimaginable journey. Despite an extensive treatment regime of 40 rounds of chemotherapy and 25 sessions of radiation, Michael passed away at the age of 50.

Determined that Michael’s death would lead to something meaningful, Michael’s wife, Linda and her family launched the Michael Sobey Foundation followed by March for Mick, an annual fundraiser supporting bowel cancer research at Garvan. Each March, participants walk 50 kilometres – one for every year of Michael’s life. In 2025, the event raised $15,000 for the lab of Professor Thomas Cox, who is working to develop new treatments for bowel cancer.

Since Michael’s passing, the family has raised over $150,000 for cancer research at multiple organisations. And they’re just getting started.

“It would be amazing if we’re still doing this in 20 years,” Linda says. “And even more amazing if by then there are better treatment options for bowel cancer because of the support we’ve been able to provide Garvan.”

At the heart of it all is hope that the next family facing a devastating diagnosis will have more time together.

We really want to put money into better treatment options. If improved treatment could give someone else 10 more years of life, imagine how many huge life events they would get to be a part of. That’s why we’re committed to supporting Garvan so that change can happen for someone else.

Linda Michael’s wife

Linda and Michael Sobey

Immunology

Research is increasingly revealing that almost every human disease interacts with, is shaped by, or can be treated through the immune system. Our scientists are committed to improving the management of immune conditions, while harnessing the power of the immune system to develop better treatments for a range of diseases.

Immunology in context

1.3 million

Australians live with an autoimmune condition

80+ autoimmune diseases have been identified

1 in 5

Australians have an allergic disease with numbers increasing

1 in 1,200

Australians have a primary immunodeficiency

By uncovering fundamental insights on how the immune system normally functions – and what goes wrong when it doesn’t – our researchers are transforming the diagnosis and treatment of a range of immune conditions, while also accelerating advances in other diseases, such as cancer.

Garvan’s immunology research Immunology Programs

Immune diseases are conditions caused by the dysfunction of the immune system, where the body’s defence system becomes overactive, underactive, or mistakenly attacks healthy cells and tissues. These include allergies, asthma, immunodeficiencies and autoimmune diseases.

At Garvan, our world-leading researchers are uncovering what drives these conditions, so that we can better diagnose, manage or treat immune diseases.

Importantly, our researchers also work at the intersection of Garvan’s other focus areas – genomics and cancer – to uncover the genetic causes of immune diseases and to understand how the body’s immune system can be used to fight cancer through new immunotherapies.

116 staff and students

13 labs and groups

20 research papers published

$1.5M+ secured in new peer-reviewed grants

Research highlights

Left arm or right arm? Why vaccination site matters for immune response

Our researchers found that receiving a booster vaccine in the same arm can generate a stronger and quicker immune response, offering insights to improve future vaccination strategies

Professor Tri Phan and his team, in collaboration with the Kirby Institute, showed that receiving a booster vaccine in the same arm as your first dose is highly beneficial.

The team found that when a vaccine is administered, specialised immune cells called macrophages become ‘primed’ inside local lymph nodes. Using advanced intravital imaging, they discovered that memory B cells interact closely with these macrophages. When a booster is given in the same location, these alerted macrophages efficiently capture the antigen in the vaccine and activate memory B cells to produce high-quality antibodies to protect against future infection.

A clinical study with human volunteers validated these findings, showing that those who received two COVID-19 mRNA vaccine doses in the same arm produced antibodies significantly faster and to a wider variety of COVID-19 variants than those who were vaccinated in different arms.

This early protection could be crucial during an outbreak to achieve herd immunity faster. Understanding these interactions may also help design new vaccines that require fewer booster shots.

This is a fundamental discovery in how the immune system organises itself to respond better to external threats – nature has come up with this brilliant system.

Professor Tri Phan Co-lead of the study

Professor Tri Phan and Dr Rama Dhenni

Immune ‘mystery molecule’ points to potential targets for allergies

A study of an immune messenger offers fresh hope for patients with allergic diseases

A Garvan study led by Professor Cindy Ma and her team discovered how the immune system controls interleukin-9 (IL-9), a messenger molecule linked to allergies, asthma and certain cancers.

Despite its involvement in many diseases, IL-9 has remained somewhat mysterious. By studying patients with rare genetic immune disorders, the team pieced together how various parts of the immune system enhance and inhibit IL-9 production. They made the surprising discovery that a type of immune cell called CD4+ T cells produce IL-9 through two different pathways. This dual regulatory system suggests that the body has a backup mechanism to ensure precise control of this molecule in various scenarios.

The research revealed that specific signals must be present to produce IL-9, but other immune molecules, such as interferon-gamma, can stop its production. Abnormal IL-9 levels are found in conditions like allergic asthma, eczema and food allergies.

Current treatments available often affect the entire immune system, leading to side effects like vulnerability to infections. The findings suggest new ways to develop targeted treatments that specifically control IL-9 production, either reducing it for allergies or increasing it to fight cancers.

‘Perfect

storm’ of mutations drives infection-triggered autoimmune disease

How chronic viral infections could lead to debilitating autoimmune conditions

The Goodnow Lab discovered how a viral infection causes autoimmune disease, disproving a long-standing theory. The research focused on hepatitis C virus (HCV) and its role in triggering cryoglobulinemic vasculitis, a disease where antibodies mistakenly attack blood vessels, damaging organs throughout the body. Previously, it was believed that viral proteins mimicked the body’s own proteins, causing it to produce antibodies against itself. However, the team revealed that chronic HCV infection continuously stimulates immune cells called B cells, causing them to mutate. This leads to a ‘perfect storm’ of genetic mutations, producing rogue B cells that drive the autoimmune disease. Using single-cell analysis and whole genome sequencing, the researchers identified these specific rogue clone B cells. These findings provide a new perspective on the origins of infection-associated autoimmune disease and novel opportunities for highly targeted treatments, including for other conditions like Guillain-Barré syndrome and multiple sclerosis, which are also linked to bacterial and viral infections.

This discovery fundamentally changes our understanding of how infections can cause autoimmune conditions. By pinpointing these rogue clones, we can better understand how to target them.

Professor Chris Goodnow

Co-lead

of the study

Professor Cindy Ma and Geetha Rao

Generated image of antibodies

Our research suggests that, in some cases, the refractory coeliac disease may be fuelled by immune cells that have acquired genetic mutations – something we’ve never been able to see before.

Professor Chris Goodnow Co-lead of the study

How we can supercharge the immune system against cancers

Garvan researchers discovered new pathways that may explain why some people respond to cancer immunotherapy while others don’t

Immunotherapy has emerged as one of the most significant advances in cancer treatment in recent decades. It works by recruiting the body’s own immune system to recognise and eliminate cancer cells. But not everyone responds equally, with some experiencing strong immune activation, while others experience no effect.

A Garvan study, led by Dr Megan Barnet and Professor Chris Goodnow sought to understand differences in response to a common cancer immunotherapy called anti-PD1. The team studied people with advanced lung cancer who responded exceptionally well to this therapy, and found that they had less active versions of a gene called NOD2, in combination with an autoimmune type reaction caused by the immunotherapy. This suggests that blocking two different mechanisms, one governed by PD-1 and the other by NOD2, combines to supercharge the immune system against cancer cells.

'Rogue’ immune cells explain why gluten-free diets fail in some patients

We identiﬁed mutated immune cells that could lead to better therapies for treatment-resistant coeliac disease

Garvan and UNSW Sydney researchers discovered why some people with coeliac disease continue to suffer debilitating symptoms despite strictly avoiding gluten. The team, co-led by Professor Chris Goodnow, used single-cell sequencing to reveal that certain immune cells in the gut of these patients carry genetic mutations. These abnormal ‘rogue’ cells drive ongoing intestinal inflammation, causing symptoms like pain and malnutrition in type 1 refractory coeliac disease.

The mutations share similarities with those seen in certain lymphomas, giving the cells a survival advantage even after gluten is eliminated from the diet. Currently, the only treatment for refractory coeliac disease is broad immunosuppression which does not specifically target these mutated cells. However, many of these cells have mutations in the JAK-STAT signalling pathway, which can already be targeted by approved drugs called JAK inhibitors.

This discovery offers opportunities for a personalised medicine approach, where refractory coeliac patients are treated based on their specific immune cell mutations, rather than broad immunosuppression.

READ MORE garvan.info/news-coeliac-trigger

This, in turn, points to the possibility that a patient’s response to immunotherapy could be boosted through several complementary pathways, leading to better treatment results.

Professor Chris Goodnow and Dr Megan Barnet

Driving precision immunology and health breakthroughs

The Angles family’s enduring philanthropic partnership is accelerating vital research into immune system disorders

Garvan is privileged to have been the beneficiary of the Angles family’s philanthropic support for close to a decade. Their commitment began with the late Emery Angles, a Garvan Partner for the Future, whose profound desire to improve the lives of others led him to become an early supporter of the Garvan-Weizmann Partnership. Mr Angles championed this collaboration from its inception, maintaining his steadfast support throughout his later years.

Mr Angles envisioned a philanthropic legacy that would endure for generations by establishing The Angles Family Foundation. Today, that generous spirit lives on through Emery's son Mark, daughter-in-law Alison and their adult children, who have thoughtfully broadened the foundation’s impact at Garvan.

The Angles Family Foundation continues to support important research designed to facilitate future medical breakthroughs. Their most recent gift to Professor Tri Phan is accelerating the Precision Immunology Program, fuelling vital work to improve the diagnosis of autoimmune diseases, supercharge vaccine responses and transform the management of allergic diseases and anaphylaxis.

We believe deeply in the power of scientific research and its potential to change lives. We are very proud to support the work being undertaken by the Garvan.

Mark and Alison Angles

Alison and Mark Angles

Genomics

Genes, and their study – known as genomics – underpin all human disease. Garvan’s genomics researchers work to accelerate the diagnosis and treatment of inherited disease, while also revealing fundamental insights into how genes regulate cellular processes, deepening our understanding of human biology.

Genomics in context

7,000+ genetic diseases have been identified

1 in 17

Australians are affected by a genetic condition

Over 50% of families with genetic conditions don't have a diagnosis

Powered by a decade of technological advances, our researchers are rapidly decoding how genes shape human health, accelerating the diagnosis of inherited and rare conditions, reducing diagnostic uncertainty for families and ensuring that genomics research reflects the true genetic diversity seen around the world.

Garvan’s genomics research

Our genomics researchers are decoding how variations in genes and their expression lead to a range of diseases or conditions.

Areas of Garvan’s genomics research include:

• Reducing the time to receive a genetic diagnosis, minimising the ‘diagnostic odyssey’ faced by patients and their families searching for answers

• Providing risk information for family members with a history of disease

• Improving the detection and treatment of rare genetic diseases

• Increasing the genetic diversity of genomic databases to ensure equitable access to genomic medical advances

• Using large-scale, single-cell gene sequencing technologies to discover fundamental insights about individual cell behaviour and population-wide genetic differences.

Genomics Programs

12 labs and groups 237 staff and students

119 research papers published

$18.4M+ secured in new peer-reviewed grants

Research highlights

A call for greater diversity in genomics

A misclassiﬁed genetic variant highlights the urgent need for inclusive genomic research to prevent the misdiagnosis of people from non-European ancestries

A study led by Associate Professor Jodie Ingles showed that a gene variant common in Oceanian communities was incorrectly classified as a potential cause of heart disease, highlighting the risk of not having sufficient diversity in genomics research.

The study investigated a variant in the cardiac troponin T gene found in two individuals of Pacific Island ancestry. While international databases suggested the variant was extremely rare and potentially disease-causing, the team found it was actually common among healthy individuals from Oceanian regions.

This misclassification occurs because major genomic datasets predominantly feature people of European descent. To address this equity gap, the OurDNA program, led by Professor Daniel MacArthur at the Centre for Population Genomics, is establishing a large-scale genomics resource for Australia’s multicultural population. Enrolling people from underrepresented communities is necessary for accurate interpretation of genetic variants and to ensure that the benefits of genetic testing benefit everyone.

In the clinic today, if I’m seeing a family of non-European ancestry, we are less likely to be able to make a genetic diagnosis. This means that not only do these families miss out on the associated benefits, but also there is a chance of misclassification and potential harm.

Associate Professor Jodie Ingles Lead of the study

Dr Alexandra Butters and Associate Professor Jodie Ingles

New study to improve detection of genetic immune conditions

Study commenced to improve the detection of genetic conditions impacting the immune system

The Genomic Evaluation of Newborn Immune Errors (GENIE) study, launched in 2025, is focusing on inborn errors of immunity (IEI), also known as primary immune deficiencies. These are a group of over 500 genetic conditions which affect the immune system and may cause increased infections, inflammation, autoimmunity, and in serious cases, death. Due to their rarity, many individuals with IEIs and their families live through decades-long ‘diagnostic odysseys’ seeking answers to their symptoms, while their health declines and possible treatments are delayed.

Led by Garvan’s Dr Isabelle Bosi and Associate Professor Owen Siggs, the GENIE study is exploring if combining a newborn’s heel prick test with whole genome sequencing – a comprehensive analysis of all genes – might improve the detection of IEIs.

The team is also exploring the potential benefits of including other analyses such as proteomics (studying total protein expression) and metabolomics (examining the products of metabolism) to the test.

Ultimately, the team hopes that this research could improve the detection of IEIs leading to earlier diagnosis and faster access to treatment opportunities for those affected.

Refining the genetic test panel for an inherited heart condition

Garvan researchers updated guidelines on which genes to include in genetic testing for more precise diagnoses

An international team of researchers led by Garvan refined a list of 29 genes that should be included in genetic testing for hypertrophic cardiomyopathy (HCM), an inherited heart condition which causes heart wall thickening that can lead to heart failure and sudden cardiac death, particularly in young people.

The study, led by Associate Professor Jodie Ingles systematically reviewed decades of evidence and confirmed nine ‘core’ genes definitively tied to the condition, alongside nine additional genes with clinical relevance. Importantly, they found that another nine genes previously associated with HCM should now be classified as ‘disputed’ due to insufficient evidence, discouraging their use in clinical testing.

Genetic testing provides critical information about family risk, and this updated list ensures results are accurate, clinically meaningful and can lead to better care for HCM. The research is expected to influence HCM testing practices globally, with several genetic testing laboratories already updating their processes based on the findings.

It’s not just about diagnosing the patient –it’s about helping families make informed decisions about their health. If we’re testing the wrong genes, we risk confusion, misclassification or unnecessary stress.

Sophie Hespe First author of

the study

Dr Isabelle Bosi and Associate

Professor Owen Siggs

For families with a rare genetic disease, the journey to a diagnosis can be long and arduous, with many patients suﬀering unnecessarily because they don’t have a clear diagnosis. If we can get them an answer today, in some cases that can lead to a targeted treatment tomorrow.

Associate Professor Owen Siggs Co-lead of the Genomics of Rare Disease Registry

National registry oﬀering hope for families with genetic heart conditions

A newly established national database aims to predict and prevent life-threatening complications from inherited cardiovascular disease

Unlike heart disease caused by lifestyle factors, inherited heart conditions are present from birth and can cause sudden cardiac arrest in young, healthy people without warning. Currently, genetic testing uncovers the underlying cause in only 40% of affected families. Even when a genetic link is identified, predicting who will develop severe complications remains a significant clinical challenge.

To address this critical knowledge gap, Garvan’s Australian Hearts Registry is gathering vital health information from thousands of individuals. Participants share their medical records and complete surveys detailing their health and family history. This creates a powerful, large-scale dataset that reveals how these conditions affect daily life and what heightens a person's risk.

Genomics of Rare Disease Registry: uncovering the underlying cause of rare diseases

Garvan launched a study to improve the diagnosis and treatment for the two million Australians with rare genetic disease

There are more than 7,000 known rare diseases, which by definition, affect fewer than 5 in 10,000 people. They can affect any organ, including the brain, eyes, heart, kidneys, and immune system, with examples including Huntington’s disease and retinitis pigmentosa. The vast majority of rare diseases are genetic, and while an estimated 8% of Australians live with a rare disease, less than half of those receive a genetic diagnosis in their lifetime.

To tackle this, the Genomics of Rare Disease Registry, led by Associate Professors Jodie Ingles and Owen Siggs was launched in 2025. The Registry is part of a national study focused on understanding the genetic causes of rare diseases, with the goal to better understand, identify and manage them. It connects families affected by an inherited rare disease to new research opportunities, including studies that can assist with finding a genetic diagnosis, and current or future treatment options.

By establishing a diverse, nationwide cohort, this registry will drive major improvements in the diagnosis, treatment and clinical care of families living with inherited heart diseases.

Associate Professor Jodie Ingles and Dr Laura Yeates

A long-standing tradition of support

How the McCusker Charitable Foundation is helping fast-track Garvan’s inﬂammatory bowel disease research

For over 50 years, the McCusker family has been a pillar of Australian philanthropy, providing leadership and more than $100 million to causes including transformative medical research. The McCusker Charitable Foundation has partnered with Garvan to tackle inflammatory bowel disease (IBD).

The Foundation directed its support towards Dr Kylie James and her team, who are using advanced genomic and bioinformatic techniques to uncover how cells in a person’s gut interact with microbes and how these interactions may underpin IBD. For the McCusker family, the motivation is deeply personal.

“The Foundation is delighted to support the important work of Dr Kylie James and her team,” says Malcolm McCusker. “In our social circle alone, I know of four young men and two young women with these conditions. These young people have their lives torn apart as they manage their illness and the cocktail of therapeutics that seem to impact each patient so uniquely.”

This support is helping fund a specialist senior bioinformatician – a role essential for integrating vast genomic and microbial datasets to identify biomarkers that could predict a person’s response to IBD therapy. Through this cutting-edge work, the Foundation is helping fast-track the development of patient-focused, precision therapies for IBD.

Research into the causes and new treatments for IBD is critical and Kylie’s research into assessing microbial networks to guide patient stratification and therapeutic treatment is cutting-edge.

Malcolm McCusker

Tonya and Malcolm McCusker

LEGACY

Our Scientific Platforms

Key technological infrastructure, services and capabilities that underpin all of Garvan’s research breakthroughs.

Garvan's Scientific Platforms couple technical expertise with cutting-edge technology and equipment. These platforms are central to our advancements in medical research and push the boundaries of what we can achieve.

Scientific Platforms Heads

Imaging

Provides researchers access to state-of-the-art microscopy and preclinical imaging. It houses Australia's largest fleet of intravital microscopes to enable visualisation of dynamic cellular states in disease models and supports researchers from experimental design through to analysis.

Data science

Provides essential expertise and support for data-intensive medical research, from AI strategy and deployment to building storage and scalable computing platforms. The team uses statistics, machine learning and AI to analyse complex datasets and significantly contributes to the development of Australia's national genomics infrastructure.

Clinical translation & engagement

Provides expertise to translate Garvan’s research into real-world impact. The platform supports researchers to return genomic information to participants for the early detection of genetic conditions as well as facilitates the participation of consumers and the community in our research programs.

Biologics

An advanced research initiative dedicated to accelerating the discovery and development of next-generation protein-based biologic therapies. Equipped with state-of-the-art technologies, the platform supports researchers across Garvan to pioneer novel biologics that address critical medical needs.

Genomics

Provides state-of-the-art genomics services to researchers at Garvan and across Australia. The platform is a leader in genomic sequencing, single-cell and spatial omics, and advanced flow cytometry and is a key enabler to our genomic breakthroughs.

Development

A unique initiative designed to drive translational and commercial projects from concept to clinical application. Supported by milestone-driven funding and market analysis, it empowers researchers to transform breakthrough discoveries into potential therapies and medical solutions.

Mary-Anne Young

Dr Jim Blackburn

Dr Rachel Galimidi

Dr Deborah Barkauskas

Associate Professor Leonard Goldstein

2025 Scientific Platform highlights

Showcasing the pivotal milestones, technological advancements and expanded capabilities achieved across our Scientific Platforms in 2025 to accelerate our medical discoveries.

Imaging

Expanded imaging capabilities

We expanded the imaging services available for researchers through the acquisition of two new imaging capabilities – the Prospect T2 ultrasound system and the FV4000 confocal microscope.

Increased access for Garvan researchers

Research use of our imaging capabilities and expert services increased by more than 30% compared with 2024.

Integrated histopathology

We integrated the existing Histopathology Facility, a strategic partnership bolstering Garvan's capacity to deliver deeper spatial insights into the efficacy of emerging treatments.

Data science

AI strategy developed

We developed an institute-wide AI strategy to embed artificial intelligence across both scientific discovery pipelines and professional operations.

Leveraging AI for scientific discovery

We pushed the boundaries for what is possible, leveraging AI to deliver innovative tools such as CABANA, a deep-learning toolkit for studying collagen architecture in human cancers.

Scalable computing ensured

Successfully completed a strategic migration from on-premises infrastructure to a modern ecosystem using external, national, university and commercial platforms.

Dynamic consent platform released

We released the open-source upgraded CTRL platform, an online dynamic patient consent solution replacing paper-based systems to address critical gaps in scalable genomics infrastructure.

Clinical

translation & engagement

Enabling consumer and community engagement

Launched and operationalised Garvan's first Consumer and Community Involvement Framework, providing clear expectations, shared tools and systems to embed meaningful consumer involvement in project planning and research governance across the Institute.

Patients supported when receiving genetic information

Supported the return of clinically actionable genetic information to 47 research participants within the Medical Genome Reference Bank. Follow-up interviews demonstrated positive experiences, with participants emphasising the benefits that this health information provided for their younger family members.

Genomics

New technologies delivered

Expanded the platform's advanced capabilities with the onboarding of four new spectral flow cytometers.

More services made available

Development

Garvan Accelerator Fund launched

We established an internal funding program to advance early-stage research into translational products, including therapeutics, diagnostics, and enabling technologies, through milestonebased investment and governance. This funding supports projects from proof-of-concept through preclinical validation, with three applications selected for funding in its first round.

Translational Research Centre advanced

We commenced the build-out of the Translational Research Centre, a centralised development infrastructure to advance therapeutic and diagnostic programs from discovery into preclinical development. It will also operate as a set of bespoke hubs that support complex biological questions in basic research.

Biologics

Specialised biologics team established

Recruiting from biotech leaders, we built a dedicated team with deep industry experience driving end-to-end antibody discovery and engineering across eight active programs.

Expanded service offerings by onboarding seven new technical workflows and achieving highly sought-after certified service provider status for five of these advanced protocols.

Broad research support

We achieved exceptional reach by supporting more than 140 researchers spanning over 55 distinct teams from internal Garvan programs and external collaborative partnerships.

Sustained biologics asset generation

We advanced a robust pipeline of over 10 discovery programs, completing two full antibody campaigns and engineering more than 50 bispecific and trispecific constructs.

Scientific impact achieved

We achieved a 10-fold affinity improvement for a lead candidate.

Awards and recognition

Celebrating the remarkable achievements of our researchers whose dedication and excellence continue to advance medical science globally.

READ MORE garvan.info/crafoord-prize-2025

READ MORE garvan.info/max-cooper-prize-2025

AI-driven mapping for pancreatic cancer

In an outstanding achievement for cancer research, Dr Brooke Pereira was awarded the prestigious Fulbright Future Scholarship. This scholarship acknowledges her innovative work using AI-driven spatial mapping to identify new treatment targets for pancreatic cancer. By studying the dense tissue surrounding tumours – the microenvironment – her research aims to overcome treatment resistance and improve outcomes for patients with this aggressive disease.

Landmark discovery earns global recognition

Established in 1980 by the Royal Swedish Academy of Sciences, the Crafoord Prize is one of the world’s most prestigious scientific honours. Professor Chris Goodnow received the 2025 prize in Polyarthritis, alongside Professor David Nemazee, for discovering the fundamental ‘checkpoints’ that normally prevent B cells from attacking the body. This groundbreaking research has transformed our understanding and treatment of autoimmune diseases.

International prize for autoimmunity research

In a remarkable year of recognition, Professor Chris Goodnow was also awarded the 2025 Max Cooper Prize in Immunology. This international honour acknowledges his significant contributions to understanding how immune tolerance mechanisms fail, leading to autoimmune diseases. By applying genomic analysis to immune cells, his work has revealed genetic causes of conditions like lupus and rheumatoid arthritis, providing vital insights into their treatment.

Advancing clinical genomics through sequencing

The Australian Academy of Science named Dr Ira Deveson as the recipient of the 2025 Ruth Stephens Gani Medal for his outstanding contributions to human genetics. This award acknowledges his innovative use of long-read sequencing to diagnose complex diseases. By partnering with Indigenous communities, his research promotes equity in genomic medicine and provides critical answers for previously undiagnosed conditions.

Dr Brooke Pereira

Dr Ira Deveson

Global leadership in genomic medicine

Professor Daniel MacArthur received the prestigious European Society of Human Genetics Award for his outstanding contributions to human genetics. As head of the Centre for Population Genomics, his work ensures that the benefits of genomic medicine reach diverse populations. He notably led the development of gnomAD, the world’s largest public database of genetic variation, which has transformed how clinicians link DNA to disease to diagnose rare conditions globally.

Other awards in 2025

Professor Antony Basten

Honorary Degree of Doctor of Medicine (honoris causa)

The University of Adelaide

Significant service to medicine, immunology and the University

Dr Xufeng (Gavin) Lin and Dr Deborah Barkauskas

Immunemap Challenge Winner

Cell Behaviour Video Classification

Challenge

International recognition for classifying complex cell behaviours using video analysis

Dr Yuki Keith

Jacqueline Goodnow & Barbara Hartley Prize

Garvan Institute of Medical Research

Recipient of the 2025 prize celebrating bold women in science

Recognition for excellence in computational biology

Named the 2025 Macquarie University Eureka Prize for Outstanding Early Career Researcher, Dr Hasindu Gamaarachchi was recognised for his transformative work in computational biology. This prestigious national honour acknowledges his breakthroughs in bridging computer science and biology to significantly reduce the computing power needed for genomic sequencing. His innovations allow complex analysis to be performed on portable devices, removing the reliance on supercomputers.

Board of Directors

Garvan’s Boards of Directors provide strategic leadership and oversight. Their expertise and commitment are essential to our progress and impact.

Garvan Institute of Medical Research

The Board of Directors of the Garvan Institute of Medical Research holds ultimate responsibility for governance, policy approval and oversight of the Institute and its controlled entities.

Mr Scott Perkins (Chair)

Nominated by St Vincent's Hospital Trustees

Ms Ilana Atlas AO (from 7 May 2025)

Nominated by Council of UNSW Sydney

The Hon Dr Annabelle Bennett AC SC (until 30 September 2025)

Nominated by St Vincent's Hospital Trustees

Professor Merlin Crossley

Nominated by Council of UNSW Sydney

Ms Sue Horlin (from 6 August 2025)

Nominated by NSW Minister for Health

Dr Kate Jeffrey (from 6 August 2025)

Nominated by Sisters of Charity

Mr Stephen Johns (Treasurer)

Nominated by Garvan Research Foundation

Dr Paul Kelly

Nominated by St Vincent's Hospital Trustees

Professor Benjamin Kile

Nominated by Garvan Board of Directors

Dr Robert Marshall

Nominated by Sisters of Charity

Ms Anna McFadgen

Nominated by Sisters of Charity

Dr Andrew Nash (from 1 October 2025)

Nominated by Garvan Research Foundation

Professor Roger Reddel AO

Nominated by Minister of State for Health of the Commonwealth

Dr Russell Scrimshaw AM

Nominated by Minister of State for Health of the Commonwealth

Dr Neil Söderlund (from 1 October 2025)

Nominated by St Vincent's Hospital Trustees

Professor Ronald Trent (until 30 September 2025)

Nominated by NSW Minister for Health

Garvan Research Foundation

The Garvan Research Foundation Board oversees the Foundation’s marketing and fundraising activities, ensuring Garvan’s innovative research is supported.

Dr Russell Scrimshaw AM (Chair)

Mr Nick Abrahams

Ms Jane Allen

Mr Michael Cannon-Brookes

Ms Susan Cato AM

Mrs Wallis Graham

Mr Rajeev Gupta

Ms Maria Halasz

Mr Bruce Liu

Ms Sally Loane

Mr John Meacock

Professor Cav Simon Mordant AO

Mr Greg Paramor AO

Ms Isabella Rich

Ms Ruth Ritchie

Ms Lauren Sutton (from 2 September 2025)

Professor Benjamin Kile (ex officio)

Mr Scott Perkins (ex officio)

Higher degree research

Developing the next generation of research leaders.

In 2025 98

we celebrated another cohort of graduates reaching an important milestone in their early research careers.

Together, their work continues to enhance Garvan’s groundbreaking research, supporting the growth of our expertise in cancer, immunology and genomics.

higher degree research students hosted 28 clinicians undertaking higher degree research 15 higher degree completions

In partnership with UNSW Sydney, Garvan is committed to supporting higher degree research training for PhD and Master of Science students, advancing scientific knowledge and strengthening the development of emerging researchers. In 2025 we supported another group of exceptional graduates.

As we acknowledge these achievements, we remain focused on fostering an environment that provides the training and resources our graduates need to contribute to advances in medical research, now and into the future.

ABOVE IMAGE: Tri Phan, Hiruna Samarakoon, Hasindu Gamaarachchi, Monica Phimmachanh, Sharissa Latham, Wunna Kyaw, David Croucher, Thomas Cox

Doctor of Philosophy (PhD)

Michael Bennett

Supervised by Jacqueline Center & Linda Perry

Enhancing the integration of fracture liaison services with primary care to improve long-term post-fracture care for people with osteoporosis

Antonia Cadell

Supervised by David Croucher, Sharissa Latham, Brooke Pereira & Paul Timpson

Characterising subcellular JNK activity in pancreatic cancer

Julia Chen

Supervised by Elgene Lim & Alexander Swarbrick

The stromal-immune landscape of triple-negative breast cancer

Pei Dai

Supervised by Tri Phan & Leslie Burnett

Optimising Genome Sequencing Data

Reanalysis in Patients with Unsolved Primary Immunodeficiencies

Lachlan Gray

Supervised by Tri Phan, Sara Ballouz & Joseph Powell

What the X chromosome can teach us about the immune system and autoimmunity

Peter Hansen

Supervised by Robert Weatheritt, Tri Phan, Scott Berry & Javier Fernandez Chamorro

Characterising a program of shared neural and neuroendocrine microexon splicing by high-content imaging

Albert Kim

Supervised by Michelle McDonald, Jacqueline Center & Christian Girgis

Prevention of rebound bone loss following withdrawal of RANKL inhibition

Wunna Kyaw

Supervised by Tri Phan, John Murray, Peter Croucher & Maurice Pagnucco

Modelling Environmental Influences on Cell Phenotype with Mechanistic and Machine Learning Approaches

Tamara Milder

Supervised by Ric Day, Jerry Greenfield, Dorit Samocha-Bonet & Sophie Stocker

Quality use of sodium-glucose cotransporter 2 inhibitors – expanding the treatment focus from glycaemic control to cardiorenal protection

Shivani Patel

Supervised by Jerry Greenfield, Cindy Ma & Spiros Fourlanos Elucidating the phenotype of autoantibody negative type 1 diabetes

Master of Science (Research)

Shruti Swamy

Supervised by Elissa Deenick & Peter Hsu

A novel Inborn Error of Immunity: description of EML4 deficiency in humans and mice

Monica Phimmachanh

Supervised by David Croucher & Sharissa Latham

Rationalising the inclusion of HDAC inhibitors with standard-ofcare chemotherapy for high-risk neuroblastoma

Carley Purcell

Supervised by Christine Chaffer, Jeff Holst & Rachel Dear

Metabolic reprogramming of cancer cell plasticity: GLUT3-dependent glycolysis promotes cancer stem cell function in triple-negative breast cancer

Hiruna Samarakoon

Supervised by Ira Deveson, Hasindu Gamaarachchi & Sri Parameswaran

Optimised Computational and Visualisation Methods to Advance Nanopore Raw Signal Analysis

Kaitlin Wyllie

Supervised by Thomas Cox, Amelia Parker, Elyse Filipe & Paul Timpson

Investigating Peroxidasin (PXDN) as a potential stromal therapeutic target in breast cancer

Our graduates embody the curiosity, commitment and collaboration that underpin research at Garvan. Their achievements reflect both the quality of their work across cancer, immunology and genomics, and the supportive research environment in which they have trained.

Professor Thomas Cox Chair, Higher Degree Committee

Shaping discovery

Our most significant research publications.

Scientific breakthroughs only achieve impact when they are shared with the research community and the public. Publishing our research is fundamental to advancing health, enabling collaboration and ensuring that discovery fuels further innovation. It transforms public support into public knowledge, fuels research worldwide and accelerates translation to clinical impact.

In 2025, Garvan delivered an outstanding publication record, reflecting the excellence, ambition and rigour of our research.

The following page showcases Garvan’s most signiﬁcant publications from the year, each appearing in journals with an impact factor of 10 or higher.

Research publications

Explore Garvan's publications and see how our research is shaping the future of health garvan.org.au/publications

Lin, H.-M.; Scheinberg, T.; Portman, N.; Kim, R.M.N.; Mellor, R.; Huynh, K.; Faulkner, A.N.; Mellett, N.A.; Davis, I.D.; James Martin, A.J.; Sullivan, D.; Joshua, A.M.; McJannett, M.; Subhash, V.; Yip, S.; Azad, A.A.; Marschner, I.C.; North, S.A.; McDermott, R.S.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Meikle, P.J.; Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304). Annals of Oncology, 36(9), 1068-1077

Dhenni, R.; Carey Hoppé, A.C.; Reynaldi, A.; Kyaw, W.; Handoko, N.T.; Grootveld, A.K.; Keith, Y.H.; Bhattacharyya, N.D.; Ahel, H.I.; Telfser, A.J.; McCorkindale, A.N.; Yazar, S.; Bui, C.H.T.; Smith, J.T.; Khoo, W.H.; Boyd, M.; Obeid, S.; Milner, B.; Starr, M.; Brilot, F.; Milogiannakis, V.; Akerman, A.; Aggarwal, A.; Davenport, M.P.; Deenick, E.K.; Chaffer, C.L.; Croucher, P.I.; Brink, R.; Goldstein, L.D.; Cromer, D.; Turville, S.G.; Kelleher, A.D.; Venturi, V.; Munier, C.M.L.; Phan, T.G. (2025). Macrophages direct location-dependent recall of B cell memory to vaccination. Cell, 188(13), 3477-3496.

Emmett, L.; Subramaniam, S.; Crumbaker, M.; Joshua, A.M.; Sandhu, S.; Nguyen, A.; Weickhardt, A.; Lee, S.-T.; Ng, S.; Francis, R.J.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Gedye, C.; Rutherford, N.K.; Kumar, A.S.R.; Pook, D.; Ramdave, S.; Nadebaum, D.P.; Voskoboynik, M.; Redfern, A.D.; MacDonald, W.; Krieger, L.; Schembri, G.; Chua, W.; Lin, P.; Horvath, L.G.; Bastick, P.; Butler, P.; Zhang, A.Y.; McJannett, M.; Thomas, H.; Langford, A.; Hofman, M.S.; James Martin, A.J.; Davis, I.D.; Stockler, M.R.; Subramaniam, S.; Nguyen, A.; Ravi Kumar, A.; Lin, P.; Butler, P.; Martin, A.J.; Zebic, D.; Mak, B.; Tankard, N.; Rana, N.; Cusick, T.; Thompson, J.; Oakes, S.; Niu, C.; Thein, T.; Ford, K.; Ristevski, N.; Yip, S.; Bills, M. (2025). Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26(3), 291-299.

Emmett, L.; Papa, N.; Subramaniam, S.; Crumbaker, M.; Nguyen, A.; Joshua, A.M.; Sandhu, S.; Weickhardt, A.; Lee, S.T.; Ng, S.; Francis, R.J.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Ayati, N.; Niu, C.; Hofman, M.S.; James Martin, A.J.; Thomas, H.; Davis, I.D.; Stockler, M.R. (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26(9), 1168-1177.

Butters, A.; Thomson, K.; Harrington, F.; Henden, N.; McGuire, K.; Byrne, A.B.; Bryen, S.J.; McGurk, K.A.; Leask, M.; Ackerman, M.J.; Atherton, J.J.; Bos, J.M.; Caleshu, C.; Day, S.M.; Dunn, K.; Hayes, I.; Juang, J.; McGaughran, J.; Nowak, N.; Parikh, V.N.; Ronan, A.; Semsarian, C.; Tardiff, J.C.; Tiemensma, M.; Merriman, T.R.; Ware, J.S.; Skinner, J.R.; MacArthur, D.; Siggs, O.M.; Bagnall, R.D.; Ingles, J. (2025). A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets. European Heart Journal, 46(15), 1446-1449

Venkat, A.; Youlten, S.E.; San-Juán, B.P.; Purcell, C.A.; Gupta, S.; Amodio, M.; Neumann, D.P.; Lock, J.G.; Westacott, A.E.; McCool, C.S.; Burkhardt, D.B.; Benz, A.; Mollbrink, A.; Lundeberg, J.; van Dijk, D.; Holst, J.; Goldstein, L.D.; Kummerfeld, S.; Krishnaswamy, S.; Chaffer, C.L. (2025). AAnet Resolves a Continuum of Spatially Localized Cell States to Unveil Intratumoral Heterogeneity. Cancer Discovery, 15(10), 2139-2165.

Young, C.; Singh, M.; Jackson, K.J.L.; Field, M.; Peters, T.J.; Angioletti-Uberti, S.; Frenkel, D.; Ravishankar, S.; Gupta, M.; Wang, J.J.; Agapiou, D.; Faulks, M.; Al-Eryani, G.; Luciani, F.; Gordon, T.P.; Reed, J.H.; Danta, M.; Carr, A.; Kelleher, A.D.; Dore, G.J.; Matthews, G.; Brink, R.; Bull, R.A.; Suan, D.; Goodnow, C.C. (2025). A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease. Immunity, 58(2), 412430.

Hespe, S.; Waddell, A.; Asatryan, B.; Owens, E.; Thaxton, C.; Adduru, M.-L.; Anderson, K.; Brown, E.E.; Hoffman-Andrews, L.; Jordan, E.; Josephs, K.; Mayers, M.; Peters, S.; Stafford, F.; Bagnall, R.D.; Bronicki, L.; Callewaert, B.; Chahal, C.A.; James, C.A.; Jarinova, O.; Landstrom, A.P.; McNally, E.M.; Murray, B.; Muiňo Mosquera, L.; Parikh, V.N.; Reuter, C.; Walsh, R.; Wayburn, B.; Ware, J.S.; Ingles, J. (2025). Genes associated with hypertrophic cardiomyopathy: a reappraisal by the ClinGen hereditary cardiovascular disease gene curation expert panel. Journal of the American College of Cardiology, 85(7), 727740.

Snaith, J.R.; Olsen, N.; Evans, J.; Kowalski, G.M.; Bruce, C.R.; Samocha-Bonet, D.; Breit, S.N.; Holmes-Walker, D.J.; Greenfield, J.R. (2025). Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial. Nature Communications, 16(1), 9884.

Gamaarachchi, H.; Stevanovski, I.; Hammond, J.M.; M Reis, A.L.; Rapadas, M.; Jayasooriya, K.; Russell, T.; Yeow, D.; Hort, Y.; Patel, C.; Mallett, A.; Stackpoole, E.; Roman, L.; Silver, L.W.; Hogg, C.J.; Streeting, L.M.; Bogdanovic, O.; Coelho Rodrigues Noronha, R.; Santos do Nascimento, L.A.; Lima Cardoso, A.; Georges, A.; Cheng, H.; Patel, H.R.; Kumar, K.R.; Mallawaarachchi, A.; Deveson, I.W. (2025). Targeted sequencing and iterative assembly of near-complete genomes. Nature Communications, 16(1), 10406.

Singh, M.; Louie, R.H.Y.; Samir, J.; Field, M.; Milthorpe, C.; Adikari, T.; Mackie, J.; Roper, E.; Faulks, M.; Jackson, K.J.L.; Calcino, A.; Hardy, M.Y.; Blombery, P.; Amos, T.G.; Deveson, I.W.; Wende, H.V.; Floor, S.N.; Read, S.A.; Shek, D.; Guérin, A.; Ma, C.; Tangye, S.; Di Sabatino, A.D.; Lenti, M.V.; Pasini, A.; Ciccocioppo, R.; Ahlenstiel, G.; Suan, D.; Tye-Din, J.A.; Goodnow, C.C.; Luciani, F. (2025). Expanded T cell clones with lymphoma driver somatic mutations accumulate in refractory celiac disease. Science Translational Medicine, 17(798), eadp6812.

Zhao, X.Y.; Zhao, B.C.; Li, H, L.; Liu, Y.; Wang, B.; Li, A.Q.; Zeng, T.S.; Hui, H.X.; Sun, J.; Cikes, D.; Gheldof, N.; Hager, J.; Mi, J.X.; Laybutt, D.R.; Deng, Y.Y.; Shi, Y.C.; Neely, G.G.; Wang, Q.P. (2025). MTCH2 suppresses thermogenesis by regulating autophagy in adipose tissue. Advanced Science, 12(17), 2416598

Alexandrou, S.; Lee, C.S.; Fernandez, K.J.; Wiharja, C.E.; Eshraghi, L.; Reeves, J.; Reed, D.A.; Portman, N.; Phan, Z.; Milioli, H.H.; Nikolić, I.; Cadell, A.L.; Croucher, D.R.; Simpson, K.J.; Lim, E.; Hickey, T.E.; Millar, E.K.A.; Alves, C.L.; Ditzel, H.J.; Caldon, C.E. (2025). JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. Journal of Experimental & Clinical Cancer Research, 44(1), 244.

Han, J.Z.R.; Phimmachanh, M.; Hastings, J.F.; Leong, K.H.; Ng, B.H.; Ni, J.; Fontaine-Titley, A.; Cadell, A.L.; O’Donnell, Y.E.; Clearwater, M.S.; Kamili, A.; Haber, M.; Norris, M.; Timpson, P.; Trahair, T.; Fletcher, J.I.; Fey, D.; Kölch, W.; Latham, S.L.; Croucher, D.R. (2025). Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma. Science Advances, 11(48), eady5599.

Chambers, C.R.; Watakul, S.; Schofield, P.; Howell, A.E.; Zhu, J.; Tran, A.M.H.; Kuepper, N.; Reed, D.A.; Murphy, K.J.; Channon, L.M.; Pereira, B.A.; Tyma, V.M.; Lee, V.; Trpceski, M.; Henry, J.; Mélénec, P.; Abdulkhalek, L.; Nobis, M.; Metcalf, X.L.; Ritchie, S.; Cadell, A.L.; Stoehr, J.; Magenau, A.; Chacon-Fajardo, D.; Chitty, J.L.; O’Connell, S.; Zaratzian, A.; Tayao, M.; Silva, A.D.; Lyons, R.J.; Goldstein, L.D.; Dale, A.; Rookyard, A.; Connolly, A.; Crossett, B.; Tran, Y.T.H.; Kaltzis, P.; Vennin, C.; Dinevska, M.; Croucher, D.R.; Samra, J.; Mittal, A.; Weatheritt, R.J.; Philp, A.; del Monte-Nieto, G.D.; Zhang, L.; Enriquez, R.F.; Cox, T.R.; Shi, Y.-C.; Pinese, M.; Waddell, N.; Sim, H.-W.; Chtanova, T.; Wang, Y.; Joshua, A.M.; Chantrill, L.; Jeffry Evans, T.R.; Gill, A.J.; Morton, J.P.; Pajic, M.; Christ, D.; Herzog, H.; Timpson, P.; Herrmann, D. (2025). Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis. Science Advances, 11(11), eadq4416.

Rao, G.; Mack, C.D.; Nguyen, T.; Wong, N.; Payne, K.; Worley, L.; Gray, P.E.; Wong, M.; Hsu, P.S.; Stormon, M.O.; Preece, K.; Suan, D.; O'Sullivan, M.; Blincoe, A.K.; Sinclair, J.; Okada, S.; Hambleton, S.; Arkwright, P.D.; Boztug, K.; Stepensky, P.; Cooper, M.A.; Bezrodnik, L.; Nadeau, K.C.; Abolhassani, H.; Abraham, R.S.; Seppänen, M.R.J.; Béziat, V.; Bustamante, J.; Forbes-Satter, L.R.; Leiding, J.W.; Meyts, I.; Jouanguy, E.; Boisson-Dupuis, S.; Uzel, G.; Puel, A.; Casanova, J.-L.; Tangye, S.; Ma, C. (2025). Inborn errors of immunity reveal molecular requirements for generation and maintenance of human CD4+ IL-9–expressing cells. Journal of Allergy and Clinical Immunology, 155(4), 1161-1178.

O’Reilly, L.; Thai, L.M.; Sue, N.; Dhenni, R.; Castro-Martinez, A.; Muñoz, M.; Rogers, M.J.; Phan, T.G.; Schmitz-Peiffer, C.; Irvine, K.M.; Biden, T.J. (2025). Acute and resolving inflammation differentially regulates beta cell function in mice via interactions between peritoneal and islet-associated macrophages. Diabetologia, 69(5), 12491264.

Competitive grants

Peer-reviewed grants awarded in 2025.

Grant funding secured in 2025 64% Australian philanthropic and societies grants 2% Affiliate Funding 15% NHMRC

$43.9M

Financial highlights

For the year ended 31 December 2025.

Statement of profit or loss

Expenditure

Statement of financial position

Thank you to our Garvan family

Our supporters are united by a shared passion to make a real diﬀerence in human health. We are deeply grateful to everyone who supported Garvan in 2025. Your philanthropic investment brings us closer to a future where all diseases are prevented, treated or cured.

Visionaries

Ainsworth 4 Foundation

Mr Len Ainsworth AM

Amadeus Energy Limited

Digital Honour Board

Visit our full Digital Honour Board here garvan.info/dhb

Australian Cancer Research Foundation

Australian Lions Childhood Cancer Research Foundation

The CLEARbridge Foundation

John Brown Cook Foundation

Mr Charles P Curran AC

Sarah Davin and Niki Scevak

Mr & Mrs Geoff and Dawn Dixon

Education Heritage Foundation

The late Mr Alan Elder

The late Lady (Mary) Fairfax AC OBE Ferris Family Foundation

In memory of Dr and Mrs Wing Kan Fok

Ms M. Fok, Ms G. Fok, Ms V. Fok

Friends of the Garvan - USA

Mrs Janice Gibson and Ernest Heine Family Foundation Goodman Foundation

Professor Chris Goodnow and Dr Suzanne Hartley

The Patricia Guest Foundation

The R T Hall Trust

The late Mr Philip Hemstritch Hillcrest Foundation

Life Governors

Accor

Allind Pty Limited

The late Mr John Armati

ASX Group

ASX Refinitiv Charity Foundation

J Holden Family Foundation

The late Pieter H Huveneers

The Johnny Kahlbetzer Family

The late Mrs Virginia Kahlbetzer

Mrs Christina Kennedy and the late Mr Trevor

Kennedy AM

The Kinghorn Foundation

Lions Clubs International Foundation

Love Your Sister Foundation

The Lumb Family

Mr Bob Magid OAM and Mrs Ruth Magid

Mr & Mrs Roy and Cindy Manassen

Mr John McMurtrie AM and Mrs Deborah McMurtrie

NAB Foundation

National Breast Cancer Foundation

The NELUNE Foundation

Ms Lysia O'Keefe

Mrs Roslyn Packer AC

Mr Greg Paramor AO and Mrs Kerry Paramor

The Paramor Family Foundation

Paspaley

The Lindsay and Heather Payne Medical Research Charitable Foundation

The Petersen Family

Petersen Family Foundation

The Petre Foundation

The Lady Proud Foundation

Rosemary Pryor Foundation

Ridley Corporation Ltd

The Bill and Patricia Ritchie Foundation

Mr Peter Rockey

Mrs Margaret Rose AM

The Ross Trust

Mr John Roth and Ms Jillian Segal AO -

The Yarranabbe Foundation

Mr Alan Rydge AM and Mrs Lynne Rydge

Mr Richard Scheinberg AM and Mrs Jacqui Scheinberg

Scrimshaw Foundation

Snow Medical Research Foundation

The late Mr Laurie Sutton AM and Mrs Di

Sutton

Suttons Motors Management

Charlie Teo Foundation

Tour de Cure

TPG Telecom Foundation

St Vincent's Curran Foundation

Mr & Mrs John and Megan Wade

Wade Civil Engineering Pty Ltd

The Walker Family Foundation

The late Mr Lang Walker AO and Mrs Sue

Walker

The late Mr David Baffsky AO and Mrs Helen Baffsky

Baxter Charitable Foundation

John and Anna Belfer Trust

BWM Isobar

De Lambert Largesse Foundation

Mr Peter Duncan AM and the late Mrs Val

Duncan

Richard Fenning & Wendy Volckman

Mr Laurence S Freedman AM

The late Miss Felicia D Garvan

The late James Patrick Garvan and Family

Mrs Agnes Ginges and the late Mr Berel Ginges

The late Mr Cyril Golding

The Goodridge Foundation

Mr William A Gruy G P Harris Foundation

Mr & Mrs Paul and Judy Hennessy

Dr & Mrs Francis and Marie Hooper

Governors

The Abey Perera Family Foundation

Antoinette Albert

Mr Ken Allen AO and the late Mrs Jill Allen

Kimberly and Toby Allen

The Angles Family Foundation

Australian Tunnelling Society in memory of Peter Watson

Belmadar Pty Ltd

Colin Biggers & Paisley

Mrs Kaye Blaiklock

Mrs Isobel Boccalatte

The Broinowski Foundation

Mrs Jane Brooks Browne Family

David Z Burger Foundation

Mr Michael Cannon-Brookes and Mrs Helen Cannon-Brookes

Tony Carr Foundation

Centenary Foundation - The Judith Hodge Fund

Dr John & Mrs Anne Chong

The Corio Foundation

Croall Foundation

Cure Cancer Australia

Mr & Mrs Kamlesh and Swati Dave

Essential Energy

The Estée Lauder Companies

John Forsyth AM and Ann Verschuer Girgensohn Foundation

Graf family

Ms Lorette Graham

Greater Melbourne Foundation through the Eldon & Anne Foote Trust

Dr Leslie Green and Mrs Ginny Green

Mr & Mrs Ralph and Lorraine Keyes

Mallesons

Mr Fred "Frog" Moore

National Australia Bank

NSW Ministry of Health

Dr Graham O’Neill

The Rodney & Judith O'Neil Foundation

The late Mr K Packer AC

George Patterson Pty Ltd Perpetual Foundation -

The Kibblewhite Endowment

Roth Charitable Foundation

Benefactors

Accenture

Australian Ladies Variety Association Inc

Mrs & Mr Deborah & John Balderstone

Mrs Dorothy Baylis and the late John Baylis

Mr Alexander Berlee

Ms Valeska Bloch

Mr Cameron Bryant

Mr & Mrs Andrew & Kate Buchanan

Melissa and Jonathon Green

Sharon Green and Marcel Skjald Endowment

GW Foundation

David and Fee Hancock

The David & Fee Hancock Foundation

Heart of the Green in loving memory of Joshua Avvenevole

David & Dulcie Henshall Foundation

Sally Herman OAM

Margaret Heuer

The Highfield Foundation

Idle Acres Foundation Imago Foundation

Phillip and Carol Isaacs

Dr George Jacobs and Dr Janice Hirshorn

Terry and Helen Jones

Alan Joyce AC and Shane Lloyd Kedje Foundation

Mr Geoffrey H Kimpton

David Lesnie Foundation

The Lewis Foundation

William Lynch Memorial Fund

Dr Lee MacCormick Edwards Charitable Foundation

Macoun Charitable Foundation

The Marrocco Family in memory of our beloved Domenico Marrocco

The McCusker Charitable Foundation

In memory of Terry McGuinness

Mostyn Family Foundation Nelumbo Trust Fund

Ms Janette Mary O'Neil

Pacific Equity Partners

Joseph Palmer Foundation

Caesar Family

Castle Harlan Inc

Mr & Mrs Stephen & Mary Charlesworth

John & Jennifer Clarke

V & C Comino Foundation

Ms Barbara Elliott

Ms Jane Farrell

Miss Julia Farrell

Mr & Mrs Tim and Sally Sims

Skipper-Jacobs Charitable Trust

The late Mr Robert Strauss MBE

The late Dr John Tonkin

Twin Towns Services Community Foundation Limited Westfield Holdings Ltd

Mr Brian White AO and Mrs Rosemary White

E J Whitten Foundation Witchery Wood Family Foundation

The Penn Foundation

Lidia Perin Foundation

Perpetual Foundation - The Felicia Garvan Endowment

Perpetual Foundation - Marles & Manning

Charitable Endowment

The Ian Potter Foundation Renshaw Foundation

Ms Jane Rich

Marina Rizzo, Santina Rizzo and Yasmina Sadiki

Mr & Mrs Stuart & Christine Robertson

Bruce Rosenberg Avrom and Lindy Sank

David and Eva Scheinberg

Dr John Schubert AO and Mrs Prue Schubert

The Schwinghammer Foundation

The Seargeant Foundation

The late Mr Walter Sheldon and Mrs Edith

Sheldon

J & D Sly

Mr & Mrs Jim & Fran Sweeny

Mr Bill Taylor

Tour de Rocks

Miss Lyn Unsworth

Mr Peter Vlandis

Wade Family Trust

The Wales Family Foundation

Richard and Susan Warburton Foundation

Webb Family

White Butterfly in loving memory of Vanessa Juresic

Ms Sally White OAM

Mr Justin H Gardener

Mr Timothy Gearing

Alan Goodwin

In memory of Carla Griffiths

Mrs Sue Howieson

Mr & Mrs Ian and Jenny Hume

Inveruglas Pty Ltd

The Hon. Peter Jacobson KC

Mr & Mrs Patrick and Beryl Keane

Professor Geoffrey Kellerman AO

John and Connie Kennedy Charitable Trust

In loving memory of Ian Kuchel

Mr Samuel Kushe

Mrs Kenny Lee

Mrs K Lettice

Tony and Lesley Little

Logan Family Foundation in memory of Gail

Marie Logan

Helen Lynch AM and Helen Bauer

Mr John Macarthur

Mr James Main

Mrs Sandra Marder

Menika Lanard Jandd Charitable Foundation

Craig Mostyn & Co Pty Ltd

Netta and Norman Niven Endowment (Dr Maggie Mackay)

Supporters

Mr Nick Abrahams

T. Adamo Family

Mr Richard Aldridge

Dr Lyn Allen

Ms Janet Anthes

Mr Ian A N Armstrong

Peter and the late Andrea G.W. Armstrong

M M Atkinson

Baillie Family Foundation

Ms Melissa J Ball

John Barbour Estate

Mr & Mrs David and Robyn Barnett

Esther Bartram

Baudish Family Foundation

Mr Stephen Borland

Mr Maurice Bourke

Ms Maree Bowman

In memory of Fl. Sargeant Michael Brown

Ms Carolyn Bunney

Dr Michael & Mrs Jennifer Burgess

Hon. Joseph Campbell KC & Mrs Jenny Campbell

Mr Leigh Campbell

Carcione Foundation in memory of Maria Caputo

In loving memory of Bonnie Cassen

Rose-Mary Cassin

Dr Carla Ceccarelli

C E Clark

Dr A Clarke

Mr Peter Cramb

Mrs Roslyn Currie

Mrs Lois Dann

Mr Rodney F Darke

Mr & Mrs Peter and Susanne de Beuzeville

Ms Susanne de Ferranti

Mr Roger Digby

Ian and Anthea Duncan

Mr & Mrs Andrew & Dawn Dunn

Mr Kenneth Dwyer

Mr Alexander Eastwell

Mr George Edwards

Mr Michael O'Dea KCSG AM and Mrs Marianne O'Dea

In loving memory of Finbarr O'Farrell

Mrs Joan Pearson Perpetual Foundation - The Stombuco Family

Legacy Endowment

Mrs Suzannah Plowman

Henry Pollack Foundation

Joan Evelyn Poole QBE Insurance

Qualtrics

Mr Sebastian Quinn

Mrs Christine Salter & Family

Mrs & Mr Juliet and Conrad Schmidt

Scleroderma Association of NSW

Mr Donald Smith

In loving memory of my beautiful mother

Goldie Stern

Ms Jacqueline Elliott

Equity Trustees Charitable Foundation – The Small Family Bequest

Ms Susan Evens

Ms Diane Ferrier

Barbara Foord Pty Ltd

Mrs Geraldine Fox-Penglis

Freilich Prescribed Private Fund

Tim Gale

Mr Phil Gardiner

Ms Susan Gardiner

Mrs Bunny Gardiner-Hill

Susan George

Mr & Mrs Clarence & Lyndal Gibbons

Roger Gilchrist

Miss Elizabeth Goodman

Mr & Mrs William & Jacqueline Goodyear

Max Gosling

Mrs Gina Grubb

In memory of Barbara Guy

Mr Allan N Hall AM

Ms Cheryl Hatch

The Hayes Family

John Head

Mrs Patricia Ann Henderson

Mr & Mrs Lionel & Gwen Hirning

Mrs Lynette A Hudson

R.G. & R.J. Imberger

Mrs Phyllis Ingerson

Lesley Isherwood

Mr Graeme Jilbert

Mr Stephen Johns

Mr Evan Jones

Professor Anthony Joshua

KANDM Group Trust

Mr William Kennedy & Ms Judith Snelson

Mr Graham Kluck

Ms Lili Koch

Geoff and Carol Lack

Mr V Lam

Mr Greg Lamont

Ms Gayle Lee

Maureen Stevenson

Dr Jeanne-Claude Strong

Mr & Mrs Peter and Diane Sturrock

Mr Robert Sturrock

Mr Harry Tamvakeras

Ms Victoria Taylor

Mrs Joy Timbrell

Mr & Mrs Richard and Sue Walsh

Mr Robert J Walsh

Ken Warriner Foundation

Ms Margaret Westmacott

Mrs Jon M Wilson

Mr J M Yorke

Zen Imports Pty Ltd

Mr Niall Lenahan

Mrs Renata Litton

Rosemary Lucas

In loving memory of our son Tim Maffey

Mrs Juliana Maher

Ms Annette Martin

Masfor Group Pty Ltd

Mr Lance Matheson

Ms Patricia McAleer

Ms Sharon McAuliffe

Mr Bruce McBryde

Mrs Jennifer McGinley

Mrs Marie McGoldrick

Heather McKenzie

Nicola McKern

Mrs Marguerite McKibbin

Miss Kathryn McQuarrie AM

Nick & Caroline Minogue Foundation

Mrs Susan Minshall

Mr John Kelvin Moody

Mr & Mrs Philip & Margaret Moore

Warren Morley

Mrs Jeannette Muggridge

Andrew & Prim Murray Family Foundation

Mrs Margaret Neyle

Hely Nominees Pty Ltd

Mr & Mrs Julian & Anne O'Neil

Jacqueline Pascual

Pathfinders

Peak Investment Partners Pty Ltd

Mrs Lesley Petsch

Mrs Almut Piatti

Dr Karla Plehwe

Betty L Price

Jennifer and Roy Randall

Mr Ken Richards

Mr Angus Richards

Reg Richardson AO

Ms Annabel Ritchie

In memory of Roger Rose

Mr David Ross

Mrs Karen Samociuk

Mr Robin Sanderson & Ms Anne Coffey

Santalum Foundation

Mr Peter Scott

Helen Seward in memory of Dennis Seward

Mrs Judith Shanahan

Enid and Leonard Shepherd Trust

Mr & Mrs Tony and Laurelle Simpson

Dick and Pip Smith Foundation

Mr Robert Spencer

Community Fundraisers

Kimberly and Toby Allen

Australian Tunnelling Society in memory of Peter Watson

Australian Ladies Variety Association Inc

Belmadar Pty Ltd

Rebecca Burn and family in memory of Aunt Danuta

In memory of William Cheung

Vella Civil Pty Ltd

In memory of Lyn Coumbis

Volunteers

Ms Justine M Flynn

Ms Claire Greaves

Mr Howard Houliston

In memory of Chris Stacy

Miss Winsome Strickland

Mr Martin Susans

Dr Peter Taylor

Theo Theodosi

Mr Ian Vale

The Elaine Walters Foundation

Elizabeth and Paul Webb

Mr Ken Wee

Judith Wheeldon AM

Mr Geoffrey White OAM

Mrs Lyn Williams AC

Ms Janet Wright

Ms Susan Wrigley

John S Young

Heart of the Green in loving memory of Joshua Avvenevole

Daniel Ianni

Robert Flint and Vivien Thomson

In celebration of Madeleine and Justin Gutman’s wedding

The Marrocco Family in memory of our beloved Domenico Marrocco

In memory of Peter Nicholson

Mr Sean O'Hara

Marina Rizzo, Santina Rizzo and Yasmina Sadiki

In memory of Laurie James Shepherd

Mrs Linda Sobey in loving memory of Michael Sobey

Robert Steiner

Mr Steve Urwin

Melissa West

Ms Janice Lam

Mrs Mairi Payten

Ms Annie Selman

Mr Kendall Webber

Estates received

We were privileged to receive bequests from the estates of these farsighted, generous people in our community. We extend our heartfelt thanks to these supporters and condolences to their loved ones and friends. Their legacies will transform the health and lives of future generations.

Gregory Adcock

Christine Allen

Bruce F Andrew

Don Anstey

John M Ball

David J Beal

Sheila Bell

Peter & Pamela Binnie

Leslie B Blackshaw

Leah Blair

Peter R Blayney

Robert J Bourke

Dr William R Bradford

John Campbell

Robert C Chadwick

Anne M Collins

Thomas R Coogan

Winifred Dane

Ruth Linda Dodd

Alfred Draper

Valerie I Drew

Michael Driscoll

Gloria R Durbin

Laszlo Eszes

Sean (John) Fahey

Alice & Maurice France

Brett A Garside

Harold Callaghan Garvan

Charles C Greeves

Shirley Gregory

Mark J Hammond

Jean D Hill

John L Irish

Rodney J Juratowitch

Shirley Kurtz

Malcolm F Lampe

David J Leavey

Madeline Lee

Nina Leibovitch

Daniel-Francois J Lemesle

Annette Lunney

Jennifer L Maffey

Doreen N E Martin

Stuart C McCulloch

Margaret A McCullough

Susan M McGrath

The late Mrs Mabs Melville

James S Milne

Norma R Minney

Jennifer J Moffatt

Freda B Moore

Harold R Muir

Francis I Murray

Caroline Needham

James T Northam

Mary T O'Neill

Delia M Ponti

Joan Evelyn Poole

Gweneira Porter

Donald R Rees

Judith A Rolfe

Wendy A Rosenthal

Julie Rundle

Elaine C Ryan

William J Seymour

Deborah R Singerman

Steven Somlai

Barbara Y Stevens

Carolyn L Symes

Margaret L Taylor

Michael & Sylvia Tracey

Ann Walker

Pamela Gaye Webb

William Roger Wood

What grows beyond you

From propagation to petri dishes, Greg’s support is helping science take root

At 74, horticultural scientist Greg sees retirement as an opportunity to dig deeper into his passions. He spends 500 hours a year volunteering at the Royal Botanic Gardens of Sydney, and has also found himself drawn to another field of discovery: the medical research taking place at the Garvan Institute.

First sparked by a friend’s involvement, his interest in Garvan deepened after attending public lectures and a tour of the Institute. "I’m in awe of the complex science that goes on there," he says. "The passion just exudes from the researchers." This engagement led him to become a regular donor, before taking things a step further when it came time to renew his Will.

Wanting to leave a lasting impact, Greg decided to become a Partner for the Future, pledging a legacy gift to Garvan in his Will. For him, it’s a natural extension of his life’s work: providing essential resources for growth. "I feel very devoted to giving some of my wealth to the betterment of medicine," he explains.

Like a true gardener, Greg understands that the most meaningful breakthroughs take time; by planting these seeds today, he is helping create the conditions for future discoveries to bloom.

I feel very devoted to giving some of my wealth to the betterment of medicine.

Greg, Partner for the Future

Partners for the Future

Our Partners for the Future are special members of the Garvan family who have left a gift to Garvan in their Will. Their generosity and vision will play a major role in Garvan’s future and help our researchers discover scientific breakthroughs that will prevent, diagnose and cure disease.

Ms Kim Abela

Ms Jane Adams

Mrs Margaret Adams

Ms Ronelle Adams

Hermelita Alcancia

Mr Richard Aldridge

Mr Ken Allen AO and the late Mrs Jill Allen

Dr Lyn Allen

In loving memory of Peter Allsopp

Mrs Linda Anderson

Mr Richard Anderson

Ms Lisa Annand

Mrs Marion Anstice

Mrs Carol Anthony

Mr Kerry Anthony

Ms Maryke Archbold-Hession

Mr Roger Arena

Mr Ian A N Armstrong

Peter and the late Andrea G.W. Armstrong

Mrs Denise Arnold

Mr Peter Askew

Margaret Atkinson

Australian Ladies Variety Association Inc

Mr John Avigdor

Ms Melissa J Ball

Emma Balldock

Ms Denise Bamford

Ms Jane Banfield

Mr & Mrs Joseph and Elizabeth (Betty) Banhidi

Mr David Barclay

Ms Robyn Barlow

Peter Bolton & Alan Barnes

Mr & Mrs David and Robyn Barnett

Miss Evelyn Barnett

Patricia Barnett

Miss Rosy Barnett

Mr Wal Barrett

David Barry

Mrs Katharine Barter

Mr Keith Barton

Esther Bartram

Mrs Karen Beales

Mr Ross Beattle

Ms Lillian Beaumont

Mrs Lynette Beaumont

Mr & Mrs Barry and Jennifer Beck

Ms James Belger

Ms Lynne Bennett

Allison Benson

Ms Elizabeth Berger

In loving memory of Tommie Bergman

Ms Suzanne Bestwick

Ms Helen Biddle

Ms Patricia Billing

Greg

Mr Trevor Bingham

Mrs Cilla Bishell

Michael O'Neill

Ms A Blake

Ms Wendy Blake

Mr Ted Blamey

Dr Rob Blank

Mrs Josephine Boniface

Ms Linda Booth

Mr Stephen Borland

Mr Ronald Boston

Mr Maurice Bourke

Ms Maree Bowman

Mrs Meryl Bowman

Mrs Helen Boyd

Alan Boyle and the late Anne Boyle

Dr Patrick Bradbery

Ms Jo Bradshaw

Mrs Barbara Brazier

Mr Robert Breakwell

Mr Peter Brell

Ms Robyn Bressington

Carolyn Bridgett

Mrs Meredith Briggs

Mr Selwyn Brindley

Robert Brisbane

Ann Bristow

Ms Julie Britchford

Mrs Jo-Ann Brittain

Edward Brogan

Philip & Wendy Brook

Ms Avril Brown

Ms Irene Brown

Dr Rebecca A Brown

Mr Norman Brownlaw

Ms Barbara Bryan

Emeritus Professor Ken Buckle

Mr Maikeli Bukasila

Mrs Anne Bunga

Mrs Elizabeth Bunyan

Dr Michael & Mrs Jennifer Burgess

In memory of Frank & Dorothy Burnett

Mr John Burton

Ms Geraldine Butler

Mrs Barbara E Buttery

Mr James Callachor

Mrs Sandra Cameron

In loving memory of Eileen & George Campbell

Dr John Campbell

Hon. Joseph Campbell KC & Mrs Jenny Campbell

Ms Margo Canavan

Miss Carolyn Cannon

Ms Maria Capner

Ms Gwynneth Carlisle

Ms Leigh Carnsew

Alan Carter

Ms Rebecca Cartwright

Ms Vicki Case

Ralph and Marie Cashman

Rose-Mary Cassin

Mrs Lorraine Cave

Dr Carla Ceccarelli

Mr Arthur Cheesman

Ms Margaret Chibnall

Dr John & Mrs Anne Chong

Ms Sue Chong

Ms Rhonda Christie

Mrs Janet Churches

C E Clark

Ms Janine E Clark

Mr Brian A Clarke

Mr Michael Coff

Ms Jill Coggan

Andrea Beattie & Julian Coghlan

Ms Anita Cohen

Dr & Mrs Roger and Carole Cole

Jeffrey Robert Collings

Jennie Collins

Mrs Jutta Collins

Ms Heather Collyer & Max Hodgson

Phillip Combe

Mr Godfrey James Comrie

Mrs Kylie Conaghan

Mrs Pamela Congdon

Dr Lynne Cook

Ms Patria Cook

Mr Paul Cook

Ms Dorothy Coombs

Mrs Isobel Cooper

Dr Rachel Costa

Miss Jacqueline Dean

Ms Elizabeth Cox

Ms Cheryl Craig

Brett Crittenden

Mrs Philippa Croker

Mrs Emilia Cross

Mr Michael Crowley

Ms Patricia Croxon

Mr Cary Cullen

Ms Maureen Curcic and Guy Curcic

Mrs Roslyn Currie

Mrs Roanne Dagg

Heinz Dahl

Mrs Lois Dann

Mr Rodney F Darke

Ms Jennifer Davies

Mr & Mrs Kevin and Sylvia Davies

Mr Michael Davies

Ms Sandra Davis

Miss Clare Dawes

Mrs Julie Dawson

Ms Leh Day

Mr Michael Day

Mr & Mrs Peter and Susanne de Beuzeville

Ms Susanne de Ferranti

Dr Chitra De Silva

Mr John Hyam & Mrs Lisa Dean-Hyam

Mr & Mrs Colin and Helen Death

Mrs Denise Debeck

Mrs Jane Deck

Mrs Diane Decker AM

Mr Ross Declerck

Mr Je DeHaan

Ms Louise Delahunty

Mr Bob Demkin

Mr & Mrs Tom and Donna Devitt

Mr John Dickens and Dr Ian Payne

Mr Roger Digby

Joe Divola

Mr John Hyam & Mrs Lisa Dean-Hyam

Mr & Mrs Colin and Helen Death

Mrs Denise Debeck

Mrs Jane Deck

Mrs Diane Decker AM

Mr Ross Declerck

Mr Je DeHaan

Ms Louise Delahunty

Mr Bob Demkin

Mr & Mrs Tom and Donna Devitt

Mr John Dickens and Dr Ian Payne

Mr Roger Digby

Joe Divola

Mr Ralph Dixon & Mrs Fionnuala Dixon

Mrs Marlene Dixon

Ms Rae Doak

Mr John Dobies

Ms Nina Dodawec

Mrs Carole Doherty & Mr John Doherty

Mrs Gabrielle Donovan

Ms Margaret Doran

Mr Peter Draper

Mr Bruce Drayton

Mrs Rickie Drewry

Dr & Mrs Bruce and Janet Duff

Jacqui Duncan

Ms Jennifer Duncan

Ms Krystyna Dunn

Brian Dunphy

Mr Alan Durham

Mr Kenneth Dwyer

Ms Mavis Eagle

Ms Judith Eburn

Ms Ziva Echtner

Mrs Lorraine Edmonds

In loving memory of Adrian Denis Edmunds

Bruce Edwardes

Mrs Elizabeth Efinger

Miss Edwina Eisenhauer

Ms Jacqueline Elliott

Lynda Ellis

Mrs Margaret Eva

The Evans Family

Ms Veronica Evans

Tanya Cannington Fagg

Mrs Wai Chiew Fairley

Ms Viv Falcone

Ms Daile Falconer and Mr Thomas Delisi

In loving memory of "Mate" Hutchen and family

Mr & Mrs Gabriel and Joan Farago

Mrs Christine Farr

Mrs Jacqueline Farrar

Mr Leighton Farrell

Mrs & Mr Featherstone

Mrs & Mr Patricia & Adam Featherstone

Ms Diane Ferrier

Mrs Frances Findley & Mrs Suzanne Allen

Ann Fitz-Gerald

Ms & Mr Carol & Desmond Fitzgerald

Mr & Mrs Charles Fletcher

Mr Paul Fletcher

Mr Thomas Flint

Mr Allan Forbes

Mrs Gail Ford OAM

Mr & Mrs N Denovan

Ms Shirley Rose Ford

Mr Paddy Forsayeth

Ms Jan Foster

In loving memory of Joy Foulsham

Mrs Geraldine Fox-Penglis

Dr & Mrs John and Diana Francis

Mr & Mrs Alan & Ruth Franklin

Mr Donald Frazer

Ms Amanda G

Mrs Cheryl Gagliano

Ms Anna Galway

Mr Quentin Gandy

"Nanny G" - Gwen Gardiner

Mrs Maria Gardiner

Ms Susan Gardiner

Mr John Gardner

Ms Geraldine Garvan

Ms Rosemary Garvan

Ms Maureen Garvey-Ross

Mrs Ann Gerald

Ms Maria Gerussi

Mrs Lucie Ghosh

Mr David Gibb

Mr & Mrs Clarence & Lyndal Gibbons

Roger Gilchrist

Lt Col Daniel R Gilfedder

Ms Elizabeth Gillespie

Mrs Margrett Gilson Girgensohn Foundation

Ms Carol Gismondi

Mr & Mrs Bill and Robyn Gleeson

Miss Edwina Glinoga

Miss Estrella Glinoga

Miss Excelsa Glinoga

Mrs Gillian Goddard

Mr Peter Goldminc

In loving memory of Tracey Goodley

Alan Goodwin

Mr & Mrs William & Jacqueline Goodyear

Mrs Robyn Goodyer

Patricia Ann Gordon

Mrs Olive J Gorringe

Max Gosling

Mrs Margaret Gowland

Mr Gary Grady

H V Graham

Mrs Marlene Grant

Mrs Peita Grant

Ms Claire Greaves

Mrs Dianne Grech

Sharon Green and Marcel Skjald Endowment

Mrs Vicki Green and Family

Ms Karen Grega

Dr Frank Gregg

Ms Patricia Griffen

Ms Samantha Grundy

Mr Michael Guerrera

The Patricia Guest Foundation

In memory of Barbara Guy

Mr Brian Hakof

Mr Allan N Hall AM

Mrs Pam Hall

Mrs Nikki Hamilton Hall

Craig Hamilton

Mrs Kristie Hannan

Mr Neil Hansford

Lynn Harnett

Mrs Carole Harris

Mr Brian Harriss

Ms Lynne Harvey

Mrs Janice Harwood

Ms Barbara Hatch

Ms Cheryl Hatch

Mrs Barbara Hayden

The Hayes Family

Ms Louise Haynes

Mrs Valerie Haynes

John Head

Ms Rosemary Heal

Ms Robyn Hearse

The late Mr Philip Hemstritch

Ms Barbara Henderson

Mr Ian Henderson

Mrs Patricia Ann Henderson

Mrs Frances Hession

Mr Scott Hession

Mrs Barbara Hewlett-Pawlow

Mr Brian Hewson

Dr Ruth Hickey

Miss Linda Hicks

Drs Peggy & TJ Higgins

Mrs Dorothy MC Hill

Mrs Judith Hill

Mr Kenneth Hillier

Ms Heather P Hindle

Mr & Mrs Lionel & Gwen Hirning

Mr Mike Hobbs

Mrs Nicole Hogan

The Rhodesian Holderness Family

Jeremy Holderness

Ms Judith Holding

Ms Jennifer Hole & Mr Lynn Bennett

Mr Alan Holland

Ms Ruth Holmes & Mr Shaun Witute

Mrs S Honer

Mrs Robyn Hopcroft

Ms Narelle Horobin

Mr Howard Houliston

Mr Brian Howard

Mr Leslie Howard

Mr Neville Howard

Mr Stewart Howarth

Mrs Berenice Howell

Mr Wayne Howson

Mrs Lynette A Hudson

Richard J Hudson

Mrs Cathryn Hunt

Mrs Lee Hunt

Mr Mircea Iancu

R.G. & R.J. Imberger

Ms Susan Imer

In memory of the late Kathrin Nell A Wilshire

Mrs Phyllis Ingerson

Ms Edith Iseli

Lesley Isherwood

Ms Fiona James

Miss Rosemary Jasic

Mrs Kay Jaumees

Dr Tatiana Jelihovsky

Mr Greg Jenkinson

Marie Jensen

Ms Grace Jerrett

Mrs Olivia Johnson

Ms Patricia Johnson

Mrs Bernadette Johnston

Mr Byram Johnston OAM and Mrs Deborah

Johnston

Ms Margaret Johnston

Terry and Helen Jones

Mr & Mrs Arthur and Elizabeth Jones

Lloyd Gwyn Jones and Barbara Jones

Dr W G Grigor

Ms S Jones

Ms Maryke Jonkman

Ms Gordana Josipovic

Isobel & Phil Kachoyan

Ms Daphne Kavassilas

Mrs Helen Kayser

Mr John Kean

Mr & Mrs Patrick and Beryl Keane

Mark Keeley

Mrs Barbara Kelley

Mr & Mrs Geoff & Isabel Kennedy

Mr William Kennedy & Ms Judith Snelson

Mr Andrew Kennett

Mrs Karenne Kenny

In loving memory of John Kerkvliet

Miss Olivia Kesby

Ms Narelle Ketelhohn

Ms Wendy Keys

Mrs Kate Khan

Mr Ashley & Mrs Gloria Kidd

Mr Bob Kijurina

Mr Frank Killion

Ms Margaret King

Mr Grant Kinsman

Mr & Mrs Jeffry and Lyn Kirby

Mr W Bruce Kirkpatrick OAM and Mrs Juliet

Kirkpatrick

Margaret Ann Knight

Ms Lili Koch

Hendrika Kramer

Mr Samuel Kushe

Ms Josie La Spina

Geoff and Carol Lack

Mr Christopher Ladd

Ms Julie Laforest

Mr Greg Lamont

Ms Gabriella Lang

Jean C Lang

Mrs Lynn Larri

Mr Barry Thompson and Ms Roberta Lauchlan

Mrs Cheryl Lavender

In loving memory of Ally Lawler

Mr Gregory Lawrence

Mary Lawson

Mr Tony Leahy

Ms Kathryn Leaney

Mrs Ella C Lee

Dr & Mrs Steven & Catherine Lee

Mrs Beth Lehman

Miss Joy Leneaux-Gale

Mr Nelson Leong

Mrs Benita Levene

Mrs Amanda Leyten

Mrs Caroline Lill

Mrs Christine Lilly

Mrs Pamela Lincolne

Mrs Shirley Lindoy JP

Mr Ryszard Linkiewicz

Mr Jeffrey Lipman

Mr Philip Lipscombe

Miss Rebecca Little

Mrs Renata Litton

Ms Jennifer Lock

Mrs Jude Logan

Miss Maureen Logan

Mr Ben Longden

Mrs Rosemarie Longhurst

Mrs Sheila Loudon

Mrs Nelis Loustrau

Susan Jane

Rosemary Lucas

Ms Rosemary Lucas-Moore

Mrs Barbara Lynch

Ms Anne MacDonald

Mr David Macreadie

Catherine Madigan

In loving memory of our son Tim Maffey

Mrs Juliana Maher

Fadhili Majaliwa

Mrs Aileen Marchiori

Ms Ruth Marendy

Dr Harry Marget

Ms Sharon Markich

Ms Annette Martin

Ms Gaye Martin

Donna Mae Mason

Dr Sam Masoud

Mr Donald Matheson

Mr Lance Matheson

Mr & Mrs Derek & Cathy Maule

Ms Sharon McAuliffe

Dr John McCririck

Mrs Maree McCusker

In loving memory of Lola McDonagh

Allison McDonald

Mrs Pam & Mr Neil McDonald

Ms Maree McDonnell

Ms Lynn McDonough

Ms Gai McDowell

Mr & Mrs Terry and Lynette McGarrigle

Mr Steven McGrath

Mrs Marguerite McKibbin

Ms Heather McLaren

Ms Bridie McLennan

In loving memory of Kenneth McLeod

Mr John Robert McLure

Mr Raymond McMichael

Mr & Mrs Kent & Dianne McNab

Miss Kathryn McQuarrie AM

Mr Martin John Meagher

Mrs Carol Meiklejohn

Ms Amanda Miles

Mr Richard Miller

Mrs Catherine Mills

Ms Sharyn Minahan

Mr Glenn Mitchell

Mr John Mitchell-Adams

Ms Eva Mitro

Mr & Mrs Keith and Marguerite Mobbs

Mrs Mary Mockler

Dorothea Mokrusch

Mary Molloy

Mr John Kelvin Moody

Mr & Mrs Philip & Margaret Moore

Mr Richard Moore

Mrs Diana and Mr Max Morison

Warren Morley

Mrs Mary Moro

Mr Christopher Morralee

Mr Raymond Morris

Mr Ross Mortensen

Mrs Jeannette Muggridge

Mr Jeff Munday

Mrs Pru Murphy

Mr Ian Murray

Mr Philip Murray

Mrs & Mr Helen & Tony Muscat

Hendrika Muskens

Ms Christine Muston

Mr Robert Muston

Ms Barbara Muzic

Ms Michele Nancarrow

Ms Anna Nathan

Mr & Mrs Michael and Valda Neels

Ms Rosemary Neville

Mr A Newland

Mrs Frances Newman

Dr R Newman

Mrs Frances Newton

Mrs Margaret Neyle

Felicity Nichols-Erikson

Dr Elizabeth Niven

Mrs Ann Norman

Mr Ronald Norman

Wayne and Gretina Norton

Mrs Wendy Norton

Mr & Mrs Novakovic

Dr Helen Nugent AC

Mr Charles Nuttall-Smith

Mr Simon Oaten

In loving memory of Maureen Marea O'Connor

In loving memory of Finbarr O'Farrell

Mr & Mrs Chris & Janelle O'Grady

Mrs Joan O'Hara

Dr Elizabeth O'Hare

Mr Kevin O'Keeffe

Mr Graham Oldfield

Mr W R O'Leary

Mr Peter Olive

Andrew O'Malley

Jason O'Rourke

Miss Christina Paap

Lady Elizabeth Page

Mr Stephen Paine

Ms Beverley Palmer

Miss Winnie Pang

In loving memory of Helen Parker

Ms Jane Parker

Ms Judith Parker

Mr & Mrs Justin and Judith Parker

Mr David Parkinson

Mrs Deborah Parkinson

Mrs Lee Parsons

Mr Cecil F Partington

Mr Chris Paspaley

Mr Rene Patat & Mr Geoffrey Priest

Nel Paterson

Mrs Joan Pearson

Ms Cynthia Peck

Ms Marianne Pedersen

Ms Anne Pender

Mr James Perham

Ms Larna Perry

Mrs Pauline Perry

Mrs Lesley Petsch

Mrs Carol Phillips

Mrs Almut Piatti

Mrs Margaret Pierce

Dr Karla Plehwe

Mr Tony Plunkett

Mrs C Pollini

Mr Alan Pollock

Mrs Jill Porritt

Mrs Elaine Porter

Lloyd and Joan Poulton

Mr William Powell

Mr & Mrs Edmund and Alviena Poznaks

Mr James and Mrs Wendy Preece

Mrs Margaret Preston

Mrs Tara Preston

Ms Andrea Pridgeon

Mrs Elizabeth Pryce

Ms Judy Radecki

Ms Margarita Rasink

Ms Barbara Ray

Mr Mike Read

Ms Juliette Reay

Ms Janet Redbond

Mr & Mrs Don and Shirley Rees

Mrs Julie Reid

Mr Kevin Reilly

Dr Judith Reynolds

Mrs Julia Richardson

Ms Denise Riley

Mr Rudi Ringger

Ms Annabel Ritchie

Ms Christine Roach

Mr Arthur Robbins

Miss Eunice Roberts

Prue Roberts

Merilyn Robertson

Mr Robert Robinson

Ms Kathy Rockwell

Ms Jacqui Rodgers

Ms Barbara Rogers

Mr & Mrs Christopher and Nancye Rolfe

Bree Roparti-Tongalea

Bruce Rosenberg

Mrs Pat Roser

Mr David Ross

Dr Edna Ross

Ms Deirdre Royer

Carole Harvey Rudd

Mrs Jennifer Ruiz

Ms Jacqueline Russell

Mrs Wendy Russell

Mr & Mrs John & Lynette Russo

Mrs Diana Rutter

Cheryl Ryan

Ms Christine Ryan

Mrs Emma Ryan

Mr George Saliba - Living with MS

Mrs Karen Samociuk

Mr Len Sanders & Ms Jan Douglas

Ms Elizabeth Sanderson

Mr Ken and Mrs Judy Sargeant

Mr Michael Sartori

Ms Bernadette Saunders

Ms Coral Saunders

Mrs Betty Saxby

Dr Lawrence K Sayer

Mrs Kristine Schmid

Dr John Schubert AO and Mrs Prue Schubert

Ms Karen Scott

Mr Peter Scott

Dr & Mrs George & M Seifert

Mrs Suzanne Selden

In memory of Rex Selman

Helen Seward in memory of Dennis Seward

Mrs Judith Shanahan

In loving memory of Robert Sharp

Leonard Graham Shaw

Mr Merv Shearman

J.F Sheehan FCA

Mr Peter Shelley

Mrs Louise Sheridan

Ms Shona Sherwin

Mrs Edith Shipway

Mr David Short

Mrs Hassanah Simpson

Jane & Barry Simpson

Ms Marianne Simpson

Mrs J Sindel-Hand

Margaret Singer

Ms Molly Slifka

Mrs Chris Smajstr

In loving memory of Cheryl Smith

Ms Claire Smith

Mrs Jillian Smith

Ms Lucia Smith

Ms Jody Somogy

In loving memory of Gianinno Soncin

Ms Kate South

Mrs Cynthia Southwell

Dr & Mrs Peter & Diana Southwell-Keely

Ms Margaret Spark

Ms Monica Sparnon

Ms Susan Spratt

Mrs Helen Spry

Ms Maureen Stepanoff

Mrs Lynne Stephen

Mr Rick Stevens

Mrs Moira Stevenson

Ms Debbie Stidiford

Ms Elizabeth Stone

Miss Winsome Strickland

Dr Jeanne-Claude Strong

Ann Stuckey

Mr & Mrs Peter and Diane Sturrock

Mr Robert Sturrock

Mr Frank Suen

Ms Janice Sullivan

Ms Susan Sutherland

Mr John Symonds

Ms Rachelle Szabason

Ms Leanne Tan

Mrs Lyn Tanner

Mr Neville Tanner

Mr Ralph Tapping

Mrs Eileen Targett

Ms Linda Taylor

Mr Craig Teece

Ms Irma Temple

Diana R. Terp

Ms Bonnie Thomas

Dawn Thomas

Ms Wendy Thompson

Fiona Tildesley

Mr Brad Timms

Mr Graham N Tindale

Ms Roslyn Tinker

Mrs Carolyn Todd

Mr Ron Tolhurst

Ross Tongue

Mr Greg Trigg

Mr Ross Tulloh

Ms Gail Turner

Ms Jennifer Turner

Miss Lyn Unsworth

Mrs Maya Van Rol

Mrs Maureen Vasquez

Ms Sherril Venn

Mr & Mrs Ian and Sharon Vette

Mr Frank Virgara

Mr Byron and Mrs Helen Vlahos

Mr & Mrs Neville and Stella Voges

Daphne Wagner

Ms Julie Wahlberg & Mr Barry Schulz AFC

Ms Verna Wakefield

Samantha Walder

Ms Roberta Walker

Miss Sandra Walker

Chris and Leigh Wallbank

Mr Alan & Mrs Karen Walsh

Mr Aubrey Walsh

Mrs Mary Walsh

Ms Rosalind Tedder Walters

Bee Ing Wan

Ms Mel War

Ms Shelley Warner

Ms Jackie Watson

Paul Wedd

Mr Francis Wedesweiler

Mr Ken Wee

Ms Heather Weir

Mr Dennis Wellbelove

Geoff Weller

Mr Andrew Wells

Gail West

Ms Lorraine West

Judith Wheeldon AM

Mrs Jan Wheeler

Ms Nicole Wheeler

Mr William Wheeler

Ms Michele White

Trevor Haines AO & Paul White

Dr Yvonne White

Mrs Helen Whittle

Mr Robert Wickenden

Ms Joan Wilkinson

Miss Sonia Willemsen

Ms Diana Williams

Mr Francis Williams

Mr & Mrs Geoffrey & Gleness Williams

Mr Geoffrey Williams

Mrs Janice (Helen) Williams

Mrs Margaret Wilson

Mrs Heather Windshuttle

Ms Merri Winter

Mrs Barbara Withers-Payne

Ms Roberta Withnall

Mr & Mrs Karl and Madeline Wolf

Mr David Wood

Mrs Claire Wotton

Ms Katherine Wray-Barnes

Mr Colin Wright

Mrs Dorothea Wright

Ms Janet Wright

Ms Pauline Wright

Ms Patricia Wynne

Mrs Elizabeth Yates

Mrs & Mr Vicki & Michael Young

Ms June Yuen

Support us Help us make discoveries that will improve health for all garvan.org.au/ar-donate Learn more Stay up to date with the latest news, events and seminars garvan.org.au/news-resources

Garvan Institute of Medical Research

384 Victoria Street, Darlinghurst

NSW, 2010 Australia

T: + 61 2 9295 8100

W: garvan.org.au